var title_f30_55_31600="Pomeroy tubal ligation B";
var content_f30_55_31600=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F51325&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F51325&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pomeroy tubal ligation B",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 298px; height: 450px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William J Mann, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_55_31600=[""].join("\n");
var outline_f30_55_31600=null;
var title_f30_55_31601="Bowing and greenstick fracture";
var content_f30_55_31601=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F52057&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F52057&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ulnar bowing with a radial greenstick fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 442px; height: 454px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bowed ulna and fractured radius in 3-year-old.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paula Schweich, MD",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_55_31601=[""].join("\n");
var outline_f30_55_31601=null;
var title_f30_55_31602="X-ray and CT of carpal boss";
var content_f30_55_31602=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F87266&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F87266&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 617px\">",
"   <div class=\"ttl\">",
"    X-ray and CT of carpal boss",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 597px; height: 294px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The lateral x-ray and CT examination reveal a carpal boss. This 40-year-old male presented with pain following trauma. A lateral radiograph (A) demonstrates a bony protuberance at the dorsal aspect of the capitate-3rd metacarpal joint (arrow). A multiplanar CT examination (B and C) was subsequently performed to evaluate for a radiographically occult fracture which more clearly demonstrates this finding, consistent with a carpal boss.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Joseph Farnam, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_55_31602=[""].join("\n");
var outline_f30_55_31602=null;
var title_f30_55_31603="Pancreatic cancer";
var content_f30_55_31603=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Pancreatic cancer (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?30/55/31603/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/55/31603/contributors\" id=\"au4783\">",
"       David P Ryan, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?30/55/31603/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/55/31603/contributors\" id=\"se4549\">",
"       Kenneth K Tanabe, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?30/55/31603/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/55/31603/contributors\" id=\"de5563\">",
"       Diane MF Savarese, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"mobipreview.htm?30/55/31603?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      INTRODUCTION",
"     </span>",
"    </p>",
"    <p>",
"     The pancreas is an organ that is situated behind the stomach (",
"     <a class=\"graphic graphic_figure graphicRef61473 \" href=\"mobipreview.htm?39/28/40388\">",
"      figure 1",
"     </a>",
"     ). Its normal function is to make hormones and digestive juices that help the body break down food.",
"    </p>",
"    <p>",
"     More than 42,000 Americans develop cancer of the pancreas each year; it is the fourth leading cause of cancer-related death in the United States. Two types of cancer can affect the pancreas:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The most common is cancer of the exocrine pancreas that originates in the pancreatic ducts (",
"       <a class=\"graphic graphic_figure graphicRef61473 \" href=\"mobipreview.htm?39/28/40388\">",
"        figure 1",
"       </a>",
"       ). The ducts are responsible for carrying pancreatic juice to the intestines. This type of pancreatic cancer, called pancreatic adenocarcinoma, is discussed in this article.",
"      </li>",
"      <li>",
"       Another type of cancer consists of a group of tumors that originate from the cells that make hormones such as insulin. These tumors are called pancreatic endocrine tumors and are not discussed here.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     More detailed information about pancreatic cancer is available by subscription. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/40/41610?source=see_link\">",
"      \"Clinical manifestations, diagnosis, and staging of exocrine pancreatic cancer\"",
"     </a>",
"     and",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/34/8746?source=see_link\">",
"      \"Surgery in the treatment of exocrine pancreatic cancer and prognosis\"",
"     </a>",
"     and",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/33/22042?source=see_link\">",
"      \"Adjuvant and neoadjuvant therapy for exocrine pancreatic cancer\"",
"     </a>",
"     and",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/37/33370?source=see_link\">",
"      \"Management of locally advanced and borderline resectable exocrine pancreatic cancer\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      PANCREATIC CANCER SYMPTOMS",
"     </span>",
"    </p>",
"    <p>",
"     Most people with pancreatic cancer have pain and weight loss, with or without jaundice (yellowing of the skin). (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/40/41610?source=see_link\">",
"      \"Clinical manifestations, diagnosis, and staging of exocrine pancreatic cancer\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Pain is common. It usually develops in the upper abdomen as a dull ache that wraps around to the back. The pain can come and go, and it might get worse after eating.",
"      </li>",
"      <li>",
"       Weight loss. Some people lose weight because of a lack of appetite, feeling full after eating only a small amount of food, or have diarrhea. The bowel movements might look greasy and float in the toilet bowl because they contain undigested fat.",
"      </li>",
"      <li>",
"       Jaundice causes yellow colored skin and whites of the eyes. Bowel movements may not be a normal brown color and instead have a grayish appearance. Jaundice is caused by a block in the flow of bile from the gallbladder, where it is stored, to the intestinal tract where the bile assists in digestion of food. The block is caused by the cancer.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      PANCREATIC CANCER DIAGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     If you develop signs or symptoms that raise suspicion for pancreatic cancer, your doctor or nurse will order one or more tests. This might include blood tests and imaging tests, like an ultrasound or CT scan,",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     an endoscopic test called endoscopic retrograde cholangiopancreatography (ERCP). (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?30/9/30865?source=see_link\">",
"      \"Patient information: ERCP (endoscopic retrograde cholangiopancreatography) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     These tests can show if there is a mass (a growth) in the pancreas and if surgery to remove the mass is possible.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Biopsy",
"     </span>",
"     &nbsp;&mdash;&nbsp;In some cases, your doctor will recommend a biopsy to confirm the diagnosis of cancer. A biopsy is a test that removes a small piece of tissue from the mass. A physician examines the tissue under a microscope to see if there are signs of cancer.",
"    </p>",
"    <p>",
"     To perform the biopsy, a doctor will use a CT scan or ultrasound to pinpoint the mass, then insert a needle into the mass and take a sample of tissue. A biopsy can sometimes be obtained using ERCP.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H5\">",
"     <span class=\"h1\">",
"      PANCREATIC CANCER STAGING",
"     </span>",
"    </p>",
"    <p>",
"     Once pancreatic cancer is diagnosed, the next step is to determine its stage. Staging is a system used to describe the aggressiveness and spread of a cancer. A pancreatic cancer's stage is based on:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The size of the cancer.",
"      </li>",
"      <li>",
"       If there are signs of cancer spread outside the pancreas on a physical exam, CT scan or MRI, chest x-ray, or other imaging tests.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     The final staging of a pancreatic cancer often depends on what is found during surgery.",
"    </p>",
"    <p>",
"     Pancreatic cancer stages range from stage I, the earliest stage, to stage IV, which means that the cancer has spread to distant organs, such as the liver. In general, lower stage cancers require less treatment than do higher stage cancers.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6825950\">",
"     <span class=\"h2\">",
"      Laparoscopy",
"     </span>",
"     &nbsp;&mdash;&nbsp;In some centers, a laparoscopy is recommended before an attempt to remove the cancer surgically to get more information about the location and size of the cancer. During a laparoscopy, the surgeon inserts a thin tube with a camera into small incisions in the belly to see the organs inside the abdomen.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H6\">",
"     <span class=\"h1\">",
"      PANCREATIC CANCER TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     Pancreatic cancer can be treated with several approaches. Early stage pancreatic cancer can often be treated and even cured with surgery. After surgery, further treatment, called adjuvant therapy, is often recommended. This might include chemotherapy or radiation therapy.",
"    </p>",
"    <p>",
"     However, surgery is often not possible; pancreatic cancer is often advanced by the time it is diagnosed. If surgery is not possible, radiation therapy chemotherapy, or both are often used to shrink the cancer, reduce symptoms, and prolong life.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Surgery for tumors in the head of the pancreas",
"     </span>",
"     &nbsp;&mdash;&nbsp;The standard operation for tumors in the head of the pancreas (",
"     <a class=\"graphic graphic_figure graphicRef61473 \" href=\"mobipreview.htm?39/28/40388\">",
"      figure 1",
"     </a>",
"     ) is a Whipple procedure (also called a pancreaticoduodenectomy). (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/34/8746?source=see_link\">",
"      \"Surgery in the treatment of exocrine pancreatic cancer and prognosis\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     In this procedure, the surgeon removes the pancreatic head, the duodenum (first part of the small intestine), part of the jejunum (the next part of the small intestine), the common bile duct, the gallbladder, and part of the stomach (",
"     <a class=\"graphic graphic_figure graphicRef68129 \" href=\"mobipreview.htm?26/37/27220\">",
"      figure 2",
"     </a>",
"     ). A modification of the Whipple procedure (a pylorus-preserving Whipple procedure) has been developed that preserves the part of the stomach (the pylorus) that is important for stomach emptying.",
"    </p>",
"    <p>",
"     In the past, complications and deaths following the Whipple procedure were high, and cure rates were less than 10 percent. However, more recent results suggest better outcomes.",
"    </p>",
"    <p>",
"     Better outcomes are possible in hospitals that perform a large number of Whipple procedures and when the surgeon is experienced with the procedure.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Surgery for tumors in the body or tail of the pancreas",
"     </span>",
"     &nbsp;&mdash;&nbsp;Because tumors in the body or tail of the pancreas do not cause the same symptoms as those in the head of the pancreas, these cancers tend to be discovered at a later stage, when they are more advanced.",
"    </p>",
"    <p>",
"     If the tumor can be removed with surgery, a laparoscopy is usually done first to make sure the cancer has not spread. If surgery is an option, part of the pancreas is removed, usually along with the spleen.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Adjuvant therapy after surgery",
"     </span>",
"     &nbsp;&mdash;&nbsp;Adjuvant (additional) therapy refers to chemotherapy, radiation, or a combination of both that is recommended for people who are thought to be at high risk of having cancer reappear (termed a recurrence or a relapse) after a tumor has been removed surgically. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/33/22042?source=see_link\">",
"      \"Adjuvant and neoadjuvant therapy for exocrine pancreatic cancer\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Even if the tumor has been completely removed, tiny cancer cells may remain in the body and grow, causing relapse after surgery. Adjuvant therapy can prolong survival by eliminating the tiny cancer cells before they have a chance to grow [",
"     <a class=\"abstract\" href=\"mobipreview.htm?30/55/31603/abstract/1-3\">",
"      1-3",
"     </a>",
"     ].",
"    </p>",
"    <p>",
"     In people with stage II or III pancreatic cancer, there are two ways to give adjuvant therapy after surgery for pancreatic cancer:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Give chemotherapy alone.",
"      </li>",
"      <li>",
"       Give a combination of chemotherapy and radiation therapy, usually followed by several months of chemotherapy alone. This strategy is called chemoradiotherapy.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     In the United States, chemoradiotherapy is recommended for most patients. Outside of the United States, patients are frequently offered chemotherapy alone.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Treatment of locally advanced pancreatic cancer",
"     </span>",
"     &nbsp;&mdash;&nbsp;Locally advanced pancreatic cancer refers to a situation where the cancer has not yet spread to distant locations in the body, but it has extended into areas around the pancreas that make it impossible to remove the tumor completely. The best treatment for locally advanced pancreatic cancer is not clear, but surgery is not usually offered. Options for treatment include chemotherapy alone or a combination of chemotherapy and radiation therapy (chemoradiotherapy). (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/37/33370?source=see_link\">",
"      \"Management of locally advanced and borderline resectable exocrine pancreatic cancer\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     In a few cases, chemoradiotherapy might be offered initially to try to shrink the tumor, followed by repeat imaging to see if surgery might be possible. &nbsp;",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h3\">",
"      Chemoradiotherapy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Chemoradiotherapy often requires a central venous access catheter (often termed a port). This is placed during surgery into one of the large blood vessels in the chest. Chemoradiotherapy also requires a portable chemotherapy pump; this is a small, battery-operated pump that fits into a pack that can be worn around the waist. The pump gives the chemotherapy medicine into the port continuously for five to six weeks.",
"    </p>",
"    <p>",
"     During this time, the patient is treated with radiation therapy five days per week. The radiation is delivered while the patient lies on a table underneath or in front of the machine. The treatment takes only a few seconds (similar to having an x-ray).",
"    </p>",
"    <p>",
"     In some cases, the chemotherapy pump is not covered by health insurance. In this case, an oral (pill) form of chemotherapy can be substituted. This treatment is taken as a pill once per day, along with radiation therapy. Radiation therapy is given five days per week. This combination probably works as well as the chemotherapy pump plus radiation therapy, although formal studies comparing the two approaches have not been done.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Treatment of stage IV (metastatic) disease",
"     </span>",
"     &nbsp;&mdash;&nbsp;For patients who are initially diagnosed with metastatic pancreatic cancer (stage IV), chemotherapy might be recommended to slow the spread of the cancer and relieve symptoms. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/12/39114?source=see_link\">",
"      \"Chemotherapy for advanced exocrine pancreatic cancer\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Chemotherapy does not cure metastatic pancreatic cancer, but it can relieve symptoms, slow disease progression, and prolong life. Talk to your doctor about the benefits and risks of chemotherapy. Your doctor might suggest participating in a clinical trial that compares new chemotherapy medicines or new combinations of treatment. (See",
"     <a class=\"local\" href=\"#H20\">",
"      'Clinical trials'",
"     </a>",
"     below.)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Treating pancreatic cancer symptoms",
"     </span>",
"     &nbsp;&mdash;&nbsp;Pancreatic cancer often causes bothersome symptoms like jaundice, intestinal blockage, pain, and weight loss. Treatments are available to relieve these symptoms. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/20/17735?source=see_link\">",
"      \"Exocrine pancreatic cancer: Palliation of symptoms\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h3\">",
"      Jaundice",
"     </span>",
"     &nbsp;&mdash;&nbsp;Jaundice is caused by a blockage of the flow of bile from the gallbladder into the intestine (",
"     <a class=\"graphic graphic_figure graphicRef68129 \" href=\"mobipreview.htm?26/37/27220\">",
"      figure 2",
"     </a>",
"     ). The most common treatment is a stent, which is a small tube that is inserted into a duct to keep it open. The stent can usually be placed in a procedure called ERCP (endoscopic retrograde cholangiopancreatography). More information on this procedure is available separately. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?30/9/30865?source=see_link\">",
"      \"Patient information: ERCP (endoscopic retrograde cholangiopancreatography) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h3\">",
"      Bowel (duodenal) blockage",
"     </span>",
"     &nbsp;&mdash;&nbsp;About 15 to 20 percent of people with pancreatic cancer will develop a blockage in the upper intestine (duodenum) caused by the tumor (",
"     <a class=\"graphic graphic_figure graphicRef61473 \" href=\"mobipreview.htm?39/28/40388\">",
"      figure 1",
"     </a>",
"     ). Surgery can be done to create a detour between the stomach and a lower part of the intestine. An alternative to bypass surgery is placement of a stent (a tube) in the duodenum. The stent helps to hold open the blocked area.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h3\">",
"      Pain",
"     </span>",
"     &nbsp;&mdash;&nbsp;Pain is a common problem in people with pancreatic cancer. In some people, pain medicine alone is all that is needed. Radiation therapy can also help relieve pain by shrinking the tumor.",
"    </p>",
"    <p>",
"     A procedure called celiac plexus block might also be a good option to control pain. This procedure uses injections of alcohol into nerves that transmit pain signals. The alcohol kills the nerves, preventing them from telling the brain to feel pain.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h3\">",
"      Weight loss",
"     </span>",
"     &nbsp;&mdash;&nbsp;Weight loss is common in people with pancreatic cancer. Taking a pancreatic enzyme replacement can help your body to absorb fat. Enzyme replacements are usually taken in a capsule on a daily basis.",
"    </p>",
"    <p>",
"     If nausea and vomiting is a problem, there are several medicines that can reduce these symptoms and improve the appetite.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H19\">",
"     <span class=\"h1\">",
"      ADVANCED CANCER AND END OF LIFE CARE",
"     </span>",
"    </p>",
"    <p>",
"     In many people with pancreatic cancer, the disease cannot be cured. Deciding when to stop treating the cancer can be difficult, and the decision should involve the patient, family, friends, and the healthcare team.",
"    </p>",
"    <p>",
"     Ending cancer treatment does not mean ending care for the patient. Hospice care is frequently recommended when a person is unlikely to live longer than six months. Hospice care involves treatment of all aspects of a patient and family's needs, including the physical (eg, pain relief), psychological, social, and spiritual aspects of suffering. This care may be given at home or in a nursing home or hospice facility, and usually involves multiple care providers, including a physician, registered nurse, nursing aide, a chaplain or religious leader, a social worker, and volunteers.",
"    </p>",
"    <p>",
"     These providers work together to meet the patient and family's needs and significantly reduce their suffering. For more information about hospice, see",
"     <a class=\"external\" href=\"file://www.hospicenet.org/\">",
"      www.hospicenet.org",
"     </a>",
"     . (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/16/32008?source=see_link\">",
"      \"Hospice: Philosophy of care and appropriate utilization in the United States\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H20\">",
"     <span class=\"h1\">",
"      CLINICAL TRIALS",
"     </span>",
"    </p>",
"    <p>",
"     Progress in treating cancer requires that better treatments be identified through clinical trials, which are conducted all over the world. A clinical trial is a carefully controlled way to study the effectiveness of new treatments or new combinations of known therapies. Ask for more information about clinical trials, or read about clinical trials at:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       <a class=\"external\" href=\"file://www.cancer.gov/clinicaltrials/learningabout/\">",
"        www.cancer.gov/clinicaltrials/learningabout/",
"       </a>",
"      </li>",
"      <li>",
"       <a class=\"external\" href=\"file://www.cancer.gov/clinicaltrials/\">",
"        www.cancer.gov/clinicaltrials/",
"       </a>",
"      </li>",
"      <li>",
"       <a class=\"external\" href=\"file://clinicaltrials.gov/\">",
"        file://clinicaltrials.gov/",
"       </a>",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H21\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H2413246629\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11171039\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/21/11602?source=see_link\">",
"      Patient information: Pancreatic cancer (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11171032\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?30/9/30865?source=see_link\">",
"      Patient information: ERCP (endoscopic retrograde cholangiopancreatography) (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H22\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/33/22042?source=see_link\">",
"      Adjuvant and neoadjuvant therapy for exocrine pancreatic cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/12/39114?source=see_link\">",
"      Chemotherapy for advanced exocrine pancreatic cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/40/41610?source=see_link\">",
"      Clinical manifestations, diagnosis, and staging of exocrine pancreatic cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/56/1929?source=see_link\">",
"      Endoscopic ultrasound in the staging of exocrine pancreatic cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/20/17735?source=see_link\">",
"      Exocrine pancreatic cancer: Palliation of symptoms",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/37/33370?source=see_link\">",
"      Management of locally advanced and borderline resectable exocrine pancreatic cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/34/8746?source=see_link\">",
"      Surgery in the treatment of exocrine pancreatic cancer and prognosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/16/32008?source=see_link\">",
"      Hospice: Philosophy of care and appropriate utilization in the United States",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Cancer Institute",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;1-800-4-CANCER",
"     <br/>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cancer.gov\">",
"      www.cancer.gov",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Society of Clinical Oncology",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cancer.net/portal/site/patient\">",
"      www.cancer.net/portal/site/patient",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Comprehensive Cancer Network",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nccn.com/\">",
"      www.nccn.com",
"     </a>",
"     )",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H23\">",
"     <span class=\"h2\">",
"      Patient support",
"     </span>",
"     &nbsp;&mdash;&nbsp;There are a number of online forums where patients can find information and support from other people with similar conditions.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       <a class=\"external\" href=\"file://about.com/\">",
"        About.com",
"       </a>",
"       Cancer Forum",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://cancer.about.com/forum\">",
"      file://cancer.about.com/forum",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"mobipreview.htm?30/55/31603/abstract/1-6\">",
"      1-6",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 13, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"mobipreview.htm?30/55/31603?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31603/abstract/1\">",
"      Regine WF, Winter KA, Abrams RA, et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA 2008; 299:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31603/abstract/2\">",
"      Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004; 350:1200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31603/abstract/3\">",
"      Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 2007; 297:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31603/abstract/4\">",
"      Yeo CJ, Cameron JL, Sohn TA, et al. Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications, and outcomes. Ann Surg 1997; 226:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31603/abstract/5\">",
"      Birkmeyer JD, Stukel TA, Siewers AE, et al. Surgeon volume and operative mortality in the United States. N Engl J Med 2003; 349:2117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31603/abstract/6\">",
"      Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25:1960.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f30_55_31603=[""].join("\n");
var outline_f30_55_31603=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           INTRODUCTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           PANCREATIC CANCER SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           PANCREATIC CANCER DIAGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H5\">",
"           PANCREATIC CANCER STAGING",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H6\">",
"           PANCREATIC CANCER TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H19\">",
"           ADVANCED CANCER AND END OF LIFE CARE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H20\">",
"           CLINICAL TRIALS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H21\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?39/28/40388\" title=\"figure 1\">",
"           Pancreas anatomy PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?26/37/27220\" title=\"figure 2\">",
"           Gallbladder anatomy PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f30_55_31604="Balsalazide: Patient drug information";
var content_f30_55_31604=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Balsalazide: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/53/8021?source=see_link\">",
"     see \"Balsalazide: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/14/37092?source=see_link\">",
"     see \"Balsalazide: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F139019\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Colazal&reg;;",
"     </li>",
"     <li>",
"      Giazo&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10026872\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat ulcerative colitis.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691244",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It may take 2 months to see the full effect.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10026871\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701587",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to balsalazide or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701559",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to aspirin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10026876\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697055",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are on a low-salt diet (this drug has salt), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10026877\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698249",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Muscle pain.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10026879\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10026874\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705343",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Capsule:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695700",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow capsule whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696305",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may sprinkle contents of capsule on applesauce. Do not chew.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705564",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Tablet:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10026875\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10026880\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10026881\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11139 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-115.25.216.6-7AD06D259D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_55_31604=[""].join("\n");
var outline_f30_55_31604=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139019\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026872\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026871\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026876\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026877\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026879\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026874\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026875\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026880\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026881\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?7/53/8021?source=related_link\">",
"      Balsalazide: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/14/37092?source=related_link\">",
"      Balsalazide: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_55_31605="Controversial areas in preoperative autologous blood donation";
var content_f30_55_31605=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Controversial areas in preoperative autologous blood donation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/55/31605/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/55/31605/contributors\">",
"     Arthur J Silvergleid, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/55/31605/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/55/31605/contributors\">",
"     Steven Kleinman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/55/31605/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/55/31605/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/55/31605/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several aspects of the provision of preoperative autologous blood donation (PAD) services remain controversial despite much experience and the apparent benefit of protecting the patient from infection. These include: extent of testing; release of infectious units; participation by known infectious donors; crossover (the release of blood not used by the autologous donor to other recipients); the use of erythropoietin; and cost-effectiveness. A review of the indications, contraindications, and technique of PAD is presented elsewhere (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/54/12134?source=see_link\">",
"     \"Preoperative autologous blood donation\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EXTENT OF TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autologous blood that will be made available for crossover must be subjected to all tests performed on allogeneic donor blood. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/41/40601?source=see_link&amp;anchor=H8#H8\">",
"     \"Laboratory testing of donated blood\", section on 'Infectious disease screening'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Autologous blood that will not be made available for crossover, but will be shipped for transfusion from the collecting to the transfusing facility, must be tested for syphilis, HbsAg, and anti-HIV-1 and HIV-2, anti-HBc and anti-HCV antibodies. Autologous blood that will be transfused within the same institution in which it is drawn need not undergo any infectious disease testing. The extent to which autologous blood (particularly in this latter category) is tested is clearly discretionary. It is, therefore, a continuing source of controversy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12144329\">",
"    <span class=\"h2\">",
"     Arguments in favor of minimal or no testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;These include: a decrease in processing costs; avoidance of the need to obtain a federal license to operate a blood collecting and processing facility; simplified bookkeeping (since nontested autologous blood cannot be crossed-over to another recipient); and avoidance of the awkward and sometimes confusing problems created by testing and the subsequent finding of abnormal laboratory test results.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12144336\">",
"    <span class=\"h2\">",
"     Arguments in favor of complete testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;These include: administrative simplicity (the chance for error is magnified whenever all collected blood is not handled in the same manner); shipping of partially tested units represents a significant administrative burden, since they must be packaged and shipped as though potentially infectious; complete testing allows for the possibility of crossover (somewhat moot, since less than 2 percent of autologous blood, if any, is actually made available for crossover); and, most important, complete testing enables the collecting facility to make appropriate decisions about the disposition of potentially infectious units (see below). It is this last argument that convinces the author that complete infectious disease testing of autologous blood is the best policy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RELEASE OF INFECTED UNITS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Continuing controversy surrounds the handling of autologous blood that tests positive for one or more infectious disease marker, particularly HBsAg, anti-HIV-1 and HIV-2, or anti-HCV; the other markers are considered less significant. There are no guidelines from the Food and Drug Association (FDA) or the AABB (formerly the American Association of Blood Banks) that address this issue. Thus, the decision as to whether or not to release test-positive blood back to the",
"    <span class=\"nowrap\">",
"     donor/patient",
"    </span>",
"    is made at the institutional level. However, both the FDA and AABB require a written statement from the receiving transfusion service and the attending physician that anti-HIV-1 positive, anti-HIV-2 repeatedly reactive, or HBsAg-confirmed reactive units are acceptable in order for them to be shipped from the collecting to a transfusing facility.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12144343\">",
"    <span class=\"h2\">",
"     Rationale for releasing infected units",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rationale for releasing autologous, test-positive blood is to protect",
"    <span class=\"nowrap\">",
"     donor/patients",
"    </span>",
"    from the adverse consequences of allogeneic blood exposure, regardless of their own infectious disease status. Support for this argument is provided by a report that allogeneic mononuclear cells may have a deleterious effect on HIV-infected patients, although this conclusion has been challenged. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/5/24665?source=see_link&amp;anchor=H11#H11\">",
"     \"Leukoreduction to prevent complications of blood transfusion\", section on 'Viral diseases'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12144350\">",
"    <span class=\"h2\">",
"     Rationale for not releasing infected units",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rationale for not releasing potentially infectious blood is to protect health care workers and to prevent transmission of an infectious disease to another patient should the known infectious unit be inadvertently transfused to the wrong patient. While both of these concerns are preventable to some extent, they are also unavoidable.",
"   </p>",
"   <p>",
"    Studies in San Francisco, for example, showed that 1.7 percent of all operations were associated with accidents involving parenteral exposure to blood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31605/abstract/1\">",
"     1",
"    </a>",
"    ]. Similarly, in response to a 1992 College of American Pathologists survey, 0.9 percent of laboratories admitted issuing an autologous unit of whole blood or red blood cells for the wrong patient; on 20 occasions, the unit was actually transfused to the wrong patient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31605/abstract/2\">",
"     2",
"    </a>",
"    ]. Such data, few as there are, support the position (endorsed by the author) of not releasing potentially infectious blood for transfusion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Participation by known infectious donors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The opposing viewpoints in this controversial area are virtually identical to those in the previous one. Arguments in favor of allowing known infected patients to participate in PAD programs were articulated in a report which, after considering civil rights issues, the Americans with Disabilities Act (ADA), and safety issues, concluded that patients infected with HIV must be permitted to provide and receive autologous blood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31605/abstract/3\">",
"     3",
"    </a>",
"    ]. Some of the complex medical, ethical and legal issues raised in this editorial were further addressed by the autologous transfusion committee of the AABB [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31605/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, others have used decision analysis to calculate the anticipated benefits of providing known infected patients with the opportunity to participate in PAD programs versus the risks to them of having to receive allogeneic blood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31605/abstract/5\">",
"     5",
"    </a>",
"    ]. The benefits attained by these known infected patients were compared with the adverse consequences potentially experienced (a calculable number) by other patients",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    health care workers inadvertently exposed to the infected blood from the autologous",
"    <span class=\"nowrap\">",
"     patient/donor.",
"    </span>",
"    The conclusion was that, given the safety of allogeneic blood, the benefit to be derived by providing patients infected with HIV, HBV, or HCV with autologous blood is very small, particularly when compared with the potential harm to health care workers (and other patients) should known infectious blood be allowed into the system. These findings lend support to our strongly held conviction that known infectious patients should not be allowed to participate in PAD programs.",
"   </p>",
"   <p>",
"    Despite the author's continuing strong opinion regarding release of infectious units and participation by known infectious donors, a caveat must be included. As outlined in Association Bulletin #98-5 of the AABB, dated September 18, 1998, The Supreme Court decision in Bragdon v. Abbott [Bragdon v. Abbott, 118 S. Ct. 2196 (1998)] specifically provides protection to HIV infected individuals under the Americans with Disabilities Act (\"ADA\"). AABB, the American Red Cross, and the Department of Defense have interpreted (and extended) this decision to HIV infected individuals wishing to participate in autologous transfusion programs, and suggest that to deny participation may run counter to the intent of the Bragdon decision. Given the issues of safety to others raised above, it is possible that the Bragdon decision may not apply to participation in autologous transfusion programs. However, the question has not specifically been addressed, and the reader is cautioned to consult with legal counsel before adopting a policy that denies either participation by known infectious donors or release of known infected blood.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CROSSOVER (RELEASE TO OTHER RECIPIENTS)",
"    </span>",
"    &nbsp;&mdash;&nbsp;When PAD programs first gained popularity, most programs allowed unused autologous blood that met all criteria applied to allogeneic blood (including medical history screening and laboratory testing) to be crossed-over (ie, made available) to recipients other than the autologous",
"    <span class=\"nowrap\">",
"     patient/donor.",
"    </span>",
"    As late as 1987, crossover was allowed in 65 percent of PAD programs; by 1990, however, only 2 percent of programs continued this practice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31605/abstract/6\">",
"     6",
"    </a>",
"    ]. While proponents argue that crossover would increase the total available blood supply and possibly reduce the overall cost of autologous blood programs, these considerations have been outweighed by concerns about the safety of autologous blood and the seemingly insurmountable logistic barriers to accurate administration of a crossover program.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12144365\">",
"    <span class=\"h2\">",
"     Safety issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Safety issues with respect to autologous blood include concerns about the",
"    <span class=\"nowrap\">",
"     patient/donor's",
"    </span>",
"    understanding of the nature of his or her illness (possibly precluding an accurate medical history); unresolved questions about the impact on safety that the patient's motivation (as contrasted with the community donor's presumed altruistic motivation) might have; and, finally, infectious disease test data, indicating a much higher frequency of viral markers in autologous as compared with volunteer donors. In study, for example, the following risk ratios for autologous versus volunteer donors were noted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31605/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      3.1 for HBsAg",
"     </li>",
"     <li>",
"      3.6 for anti-HBc",
"     </li>",
"     <li>",
"      4.2 for anti-HIV-1",
"     </li>",
"     <li>",
"      1.3 for elevated ALT",
"     </li>",
"     <li>",
"      5.7 for RPR",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12144372\">",
"    <span class=\"h2\">",
"     Logistical problems",
"    </span>",
"    &nbsp;&mdash;&nbsp;Logistical problems include the reluctance of many surgeons to release autologous blood until so late in its dating period that it is difficult to guarantee its use for another patient; the necessity to make a separate determination for each unit donated as to its eligibility for crossover; and the increase in complexity of record keeping and billing for a relatively small return in terms of the number of units added to the system. For the above reasons, the author feels that crossover of autologous blood is inappropriate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12144379\">",
"    <span class=\"h2\">",
"     Cost issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Crossover is also not a solution to the ever increasing cost of PAD programs. To the contrary, it has been argued that resources could actually be saved if what little crossover is done were eliminated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31605/abstract/8\">",
"     8",
"    </a>",
"    ]. The most appropriate response to the increase in wastage that has accompanied the rise in participation in PAD programs is to minimize overcollection by educating physicians and patients concerning appropriate donation policies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     ROLE OF ERYTHROPOIETIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite much excitement about the potential value of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/48/2825?source=see_link\">",
"     recombinant human erythropoietin",
"    </a>",
"    (r-huEPO) in the perioperative setting, there appears to be only a limited role for r-huEPO as an adjunct to more conventional blood conservation techniques. Its routine use in autologous donors seems to be unjustified [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31605/abstract/9\">",
"     9",
"    </a>",
"    ]. r-huEPO is primarily indicated in those patients in a PAD program who are anemic prior to the first donation or who have small blood volumes and would otherwise be unable to meet their anticipated needs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31605/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. The dose has ranged from 12,000 to 40,000 units per week (given subcutaneously) and iron replacement is given concurrently (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/11/37046?source=see_link\">",
"     ferrous sulfate",
"    </a>",
"    or its equivalent at a dose of 325 mg orally three times per day, if tolerated). R-huEPO can also be used to correct anemia preoperatively in selected patients who, for religious reasons, for example, refuse both allogeneic and autologous blood. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/46/10986?source=see_link\">",
"     \"The approach to the patient who refuses blood transfusion\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     COST-EFFECTIVENESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the last few years, a number of studies have been performed using the decision-analysis model in an attempt to assess the cost-effectiveness of various medical interventions. These models evaluated costs and all potential outcomes, comparing participants in the intervention (such as PAD) with nonparticipants, and expressed cost-effectiveness in dollars per quality-adjusted year of life saved (QALY). Given the increasing safety of allogeneic blood and the tremendous wastage of autologous blood, it is no surprise that PAD is not cost-effective. What is surprising is the magnitude of the cost-",
"    <strong>",
"     in",
"    </strong>",
"    effectiveness. Depending upon the age of the patient and the likelihood that blood would be transfused, the cost-effectiveness of autologous transfusion ranges from $235,000 to over $23 million per QALY saved [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31605/abstract/12\">",
"     12",
"    </a>",
"    ]. In actuality, substituting autologous for allogeneic blood results in little expected health benefit, 0.0002 to 0.00044 QALY (1.8 to 3.8 hours) saved per unit, at an additional cost per unit of $68 to $4,783.",
"   </p>",
"   <p>",
"    It is clear that however one chooses to define the upper limit of cost-effective medical care (eg, $50,000, $100,000), this level is almost always exceeded by the cost of PAD. Some have suggested that there are other, intangible factors that justify this huge expense [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31605/abstract/13\">",
"     13",
"    </a>",
"    ]. This issue, whether society will be willing to continue to expend scarce resources on autologous donation while more cost effective practices are not universally available, will need to be addressed by public policy makers. At present, the best that the clinician can do is to decrease inappropriate utilization of PAD in circumstances where the likelihood of a transfusion being required is remote [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31605/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?26/12/26820?source=see_link\">",
"       \"Patient information: Blood donation and transfusion (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12144321\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several aspects of the provision of preoperative autologous blood donation (PAD) services remain controversial despite much experience and the apparent benefit of protecting the patient from infection. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Extent of testing (see",
"      <a class=\"local\" href=\"#H2\">",
"       'Extent of testing'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Release of infectious units (see",
"      <a class=\"local\" href=\"#H3\">",
"       'Release of infected units'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Participation by known infectious donors (see",
"      <a class=\"local\" href=\"#H4\">",
"       'Participation by known infectious donors'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Release of blood not used by the autologous donor to other recipients (see",
"      <a class=\"local\" href=\"#H5\">",
"       'Crossover (release to other recipients)'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Use of erythropoietin (see",
"      <a class=\"local\" href=\"#H6\">",
"       'Role of erythropoietin'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Cost-effectiveness (see",
"      <a class=\"local\" href=\"#H7\">",
"       'Cost-effectiveness'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12144547\">",
"    <span class=\"h2\">",
"     Conclusions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Depending upon the age of the patient and the likelihood that blood would be transfused, the cost-effectiveness of autologous transfusion ranges from $235,000 to over $23 million per quality adjusted year of life saved (QALY). At present, the best that the clinician can do is to decrease inappropriate utilization of PAD in circumstances where the likelihood of a transfusion being required is remote.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31605/abstract/1\">",
"      Gerberding JL, Littell C, Tarkington A, et al. Risk of exposure of surgical personnel to patients' blood during surgery at San Francisco General Hospital. N Engl J Med 1990; 322:1788.",
"     </a>",
"    </li>",
"    <li>",
"     College of American Pathologists, Comprehensive Transfusion Medicine Survey. Set J-C, 1992.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31605/abstract/3\">",
"      Mintz PD. Participation of HIV-infected patients in autologous blood programs. JAMA 1993; 269:2892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31605/abstract/4\">",
"      Yomtovian R, Kelly C, Bracey AW, et al. Procurement and transfusion of human immunodeficiency virus-positive or untested autologous blood units: issues and concerns: a report prepared by the Autologous Transfusion Committee of the American Association of Blood Banks. Transfusion 1995; 35:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31605/abstract/5\">",
"      Vanston V, Smith D, Eisenstaedt R. Should patients with human immunodeficiency virus infection or chronic hepatitis donate blood for autologous use? Transfusion 1995; 35:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31605/abstract/6\">",
"      Devine P, Postoway N, Hoffstadter L, et al. Blood donation and transfusion practices: the 1990 American Association of Blood Banks Institutional Membership Questionnaire. Transfusion 1992; 32:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31605/abstract/7\">",
"      Starkey JM, MacPherson JL, Bolgiano DC, et al. Markers for transfusion-transmitted disease in different groups of blood donors. JAMA 1989; 262:3452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31605/abstract/8\">",
"      Kruskall MS, Yomtovian R, Dzik WH, et al. On improving the cost-effectiveness of autologous blood transfusion practices. Transfusion 1994; 34:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31605/abstract/9\">",
"      Goodnough LT, Price TH, Friedman KD, et al. A phase III trial of recombinant human erythropoietin therapy in nonanemic orthopedic patients subjected to aggressive removal of blood for autologous use: dose, response, toxicity, and efficacy. Transfusion 1994; 34:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31605/abstract/10\">",
"      Mott LS, Bechinski J, Jones MJ. Autologous blood collection in anemic patients using low-dose erythropoietin therapy. J Natl Med Assoc 1997; 89:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31605/abstract/11\">",
"      Nuttall GA, Santrach PJ, Oliver WC Jr, et al. Possible guidelines for autologous red blood cell donations before total hip arthroplasty based on the surgical blood order equation. Mayo Clin Proc 2000; 75:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31605/abstract/12\">",
"      Etchason J, Petz L, Keeler E, et al. The cost effectiveness of preoperative autologous blood donations. N Engl J Med 1995; 332:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31605/abstract/13\">",
"      Rutherford CJ, Kaplan HS. Autologous blood donation--can we bank on it? N Engl J Med 1995; 332:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31605/abstract/14\">",
"      Billote DB, Glisson SN, Green D, Wixson RL. A prospective, randomized study of preoperative autologous donation for hip replacement surgery. J Bone Joint Surg Am 2002; 84-A:1299.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7933 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-219.243.220.100-CF9D26F5DA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_55_31605=[""].join("\n");
var outline_f30_55_31605=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12144321\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EXTENT OF TESTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12144329\">",
"      Arguments in favor of minimal or no testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12144336\">",
"      Arguments in favor of complete testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RELEASE OF INFECTED UNITS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12144343\">",
"      Rationale for releasing infected units",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12144350\">",
"      Rationale for not releasing infected units",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Participation by known infectious donors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CROSSOVER (RELEASE TO OTHER RECIPIENTS)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12144365\">",
"      Safety issues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12144372\">",
"      Logistical problems",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12144379\">",
"      Cost issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      ROLE OF ERYTHROPOIETIN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      COST-EFFECTIVENESS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12144321\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12144547\">",
"      Conclusions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/41/40601?source=related_link\">",
"      Laboratory testing of donated blood",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/5/24665?source=related_link\">",
"      Leukoreduction to prevent complications of blood transfusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?26/12/26820?source=related_link\">",
"      Patient information: Blood donation and transfusion (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/54/12134?source=related_link\">",
"      Preoperative autologous blood donation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/46/10986?source=related_link\">",
"      The approach to the patient who refuses blood transfusion",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_55_31606="Lymphatic filariasis map";
var content_f30_55_31606=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F81417&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F81417&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 627px\">",
"   <div class=\"ttl\">",
"    Lymphatic filariasis map",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 607px; height: 461px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Countries where lymphatic filariasis is endemic and status of mass drug administration (MDA) in those countries, 2010.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: World Health Organization. Global Programme to eliminate lymphatic filariasis: progress report on mass drug administration, 2010. Wkly Epidemiol Rec 2011; 86:377. Available at:",
"     <a href=\"file://www.who.int/wer/2011/wer8635.pdf\" target=\"_blank\">",
"      file://www.who.int/wer/2011/wer8635.pdf",
"     </a>",
"     . Copyright &copy; 2011 World Health Organization.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_55_31606=[""].join("\n");
var outline_f30_55_31606=null;
var title_f30_55_31607="Growth failure after childhood cancer: Role of growth hormone deficiency";
var content_f30_55_31607=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Growth failure after childhood cancer: Role of growth hormone deficiency",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/55/31607/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/55/31607/contributors\">",
"     Susan R Rose, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/55/31607/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/55/31607/contributors\">",
"     David G Poplack, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/55/31607/contributors\">",
"     John L Kirkland, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/55/31607/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/55/31607/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/55/31607/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cause of poor growth in childhood cancer survivors cannot always be identified. Often it is caused by the toxic effects of chemotherapy, radiation effects on bone growth centers, hypothyroidism, or growth hormone (GH) deficiency.",
"   </p>",
"   <p>",
"    The normal regulation of GH secretion and the diagnosis and treatment of GH deficiency in childhood cancer survivors are reviewed here. Hypothyroidism and bone problems after childhood cancer are discussed separately (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/19/39223?source=see_link\">",
"     \"Growth failure after childhood cancer: Role of hypothyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/27/4538?source=see_link\">",
"     \"Bone problems in childhood cancer patients\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS FOR GROWTH FAILURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The growth rate of children who are undergoing treatment for cancer typically is slow. The slow growth velocity may result from neuraxis, mantle, or total body irradiation, chemotherapy, decreased nutritional intake, increased metabolic needs, or intercurrent illness (",
"    <a class=\"graphic graphic_figure graphicRef66717 \" href=\"mobipreview.htm?39/2/39968\">",
"     figure 1",
"    </a>",
"    ). The growth rate usually improves or shows \"catch up\" after completion of therapy (",
"    <a class=\"graphic graphic_figure graphicRef66717 \" href=\"mobipreview.htm?39/2/39968\">",
"     figure 1",
"    </a>",
"    ). Children whose growth rate does not improve or whose growth rate is less than the mean for age and gender should be evaluated for growth failure. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/18/10537?source=see_link\">",
"     \"Causes of short stature\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Growth failure in childhood cancer survivors is caused by [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31607/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cranial irradiation",
"     </li>",
"     <li>",
"      Radiation to growth centers (eg, in bone marrow transplant recipients)",
"     </li>",
"     <li>",
"      Radiation to the spine",
"     </li>",
"     <li>",
"      Inadequate weight gain",
"     </li>",
"     <li>",
"      Chronic unresolved illness",
"     </li>",
"     <li>",
"      Depression",
"     </li>",
"     <li>",
"      Hormone deficiency",
"     </li>",
"     <li>",
"      Hypothalamic-pituitary disorders secondary to tumor, surgery, chemotherapy, or cranial irradiation (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/38/9833?source=see_link\">",
"       \"Causes of hypopituitarism\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Late growth failure is common in children who received cranial body irradiation and chemotherapy. In particular, cranial radiotherapy causes GH, gonadotropin, and thyrotropin deficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31607/abstract/3-10\">",
"     3-10",
"    </a>",
"    ]. Spinal irradiation may result in poor growth of the spine, with relative sparing of limb growth. Primary hypothyroidism can occur if the thyroid gland was in the radiation field. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/22/37226?source=see_link\">",
"     \"Complications of cranial irradiation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    GH deficiency commonly is thought to be the first hypothalamic-pituitary deficiency to emerge after radiation therapy, followed by gonadotropin, ACTH, and TSH; however, these deficiencies can occur in any order [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31607/abstract/11\">",
"     11",
"    </a>",
"    ]. Hypothyroidism is at least as prevalent as is GH deficiency in cancer survivors when sensitive testing methods are used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31607/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/19/39223?source=see_link\">",
"     \"Growth failure after childhood cancer: Role of hypothyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/7/7286?source=see_link\">",
"     \"Endocrine surveillance in childhood cancer survivors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     REGULATION OF GROWTH HORMONE SECRETION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Like TSH, GH is synthesized in cells in the anterior pituitary gland in response to hypothalamic releasing hormones. GH-releasing hormone (GHRH) and somatostatin are transported through the venous portal system from the hypothalamus. GHRH secretion usually is steady, whereas somatostatin secretion is interrupted intermittently. Somatostatin contributes to synthesis of GH in the pituitary but inhibits release. When somatostatin concentrations fall, the tonic concentration of GHRH causes release of GH into the systemic circulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31607/abstract/13\">",
"     13",
"    </a>",
"    ]. Additional factors, such as neuropeptide Y, leptin, galanin, and ghrelin, also play roles in regulation of GH secretion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31607/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. In normal children and adults, GH secretion is pulsatile particularly during sleep, with two to six pulses per night [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31607/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. In adolescents, additional pulses occur during the day and the pulses have higher peaks. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/30/25059?source=see_link\">",
"     \"Hypothalamic-pituitary axis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/1/43030?source=see_link\">",
"     \"Physiology of growth hormone\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Circulating serum GH stimulates production of insulin-like growth factor (IGF-I) in all tissues. IGF-I mediates GH effects on growth and body composition (decreased fat deposition, and increased bone mineral and muscle mass) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31607/abstract/18\">",
"     18",
"    </a>",
"    ]. IGF-I is transported in the blood bound to IGF-binding proteins such as IGF-binding protein 3 (IGFBP3). IGFBP3 concentrations are stable during the day and reflect the integrated concentration of secreted GH.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     GROWTH HORMONE DEFICIENCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Altered GH secretion is an important and well-documented cause of poor growth in childhood cancer survivors, particularly after cranial irradiation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31607/abstract/10,19-21\">",
"     10,19-21",
"    </a>",
"    ]. GH deficiency in children also may contribute to development of obesity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31607/abstract/22\">",
"     22",
"    </a>",
"    ]. Hypothalamic function is affected more than pituitary function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31607/abstract/23\">",
"     23",
"    </a>",
"    ]. In most patients with GH deficiency, the deficiency is of hypothalamic GHRH and somatostatin, with reduced amplitude of GH peaks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31607/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. In a prospective study, 7 of 10 children with medulloblastoma and growth failure had abnormal spontaneous secretion of GH but normal GH responses to provocative stimuli, suggesting neurosecretory or regulatory dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31607/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Cranial irradiation and chemotherapy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H111022779\">",
"    <span class=\"h3\">",
"     Cranial irradiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The occurrence of GH deficiency after cranial irradiation is related to the total radiation dose, use of fractional doses, age of the patient at time of radiation, and duration since irradiation.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dosing &ndash; Several studies noted that cranial radiation doses greater than 24 Gy result in GH deficiency in up to two-thirds of patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/55/31607/abstract/2,27-29\">",
"       2,27-29",
"      </a>",
"      ]. In younger children, GH deficiency results from lower doses.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Doses of only 12 to 14 Gy total body irradiation combined with chemotherapy for bone marrow transplant pose significant risk for GH deficiency [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/55/31607/abstract/26,29\">",
"       26,29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In children with brain tumors (n = 192), a mean cumulative dose of 16.1 Gy to the hypothalamus was associated with a 50 percent risk of growth hormone deficiency five years from the time of irradiation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/55/31607/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among 59 childhood survivors of nasopharyngeal carcinoma, 43 percent developed primary hypothyroidism, and 14 percent developed GH deficiency at 15 year follow-up [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/55/31607/abstract/30\">",
"       30",
"      </a>",
"      ]. All patients received radiotherapy to the primary tumor, and most received cervical radiation therapy. A dose-response relationship was noted between the radiotherapy dose and the risk of GH deficiency.",
"     </li>",
"     <li>",
"      In a prospective study, all 21 children treated with more than 45 Gy for optic pathway tumor developed GH deficiency and significant height loss two years after irradiation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/55/31607/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A large fraction size of radiation administered over a short period of time is more likely to cause GH deficiency than is the same total dose administered in smaller fractions over a longer period of time [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/55/31607/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a systematic review of the literature, methodologic problems were noted in all but three of 33 studies of GH deficiency after cranial irradiation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/55/31607/abstract/32\">",
"       32",
"      </a>",
"      ]. In these three studies, the prevalence of GH deficiency ranged from 29 to 39 percent based on a clear peak GH cutoff of 5",
"      <span class=\"nowrap\">",
"       mcg/L.",
"      </span>",
"      Variation in the prevalence of GH deficiency could be explained by differences in cranial radiation therapy dose.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H111022788\">",
"    <span class=\"h3\">",
"     Chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chemotherapy alone is associated with growth impairment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31607/abstract/33\">",
"     33",
"    </a>",
"    ] and with development of GH deficiency but at a much lower rate than that of radiotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31607/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. Approximately 4 percent of oncology survivors evaluated because of slow growth had GH deficiency after chemotherapy alone. It is not known which chemotherapy agents are responsible for GH deficiency because multiple agents typically are used together. However, hypothalamic dysfunction has been seen after chemotherapy alone for several different types of noncranial tumors (leukemia, neuroblastoma, rhabdomyosarcoma).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;GH deficiency should be considered in children who have a slow growth rate and a medical history that puts them \"at risk\" for GH deficiency. Serum IGF-1 and IGFBP3 concentrations should be measured, and further evaluation is indicated if these results are below the mean for normal children of the same age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31607/abstract/36\">",
"     36",
"    </a>",
"    ]. In addition, a bone age should be obtained. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/5/82?source=see_link&amp;anchor=H8#H8\">",
"     \"Diagnosis of growth hormone deficiency in children\", section on 'Diagnostic approach'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The combination of history of cranial or total body radiation, slow growth rate, normal weight gain, no intercurrent illness, delayed bone maturation, and levels of IGF-1 and IGFBP3 less than &ndash;1 SD for age, usually are diagnostic of GH deficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31607/abstract/36\">",
"     36",
"    </a>",
"    ]. The diagnosis should be confirmed by provocative GH testing. Evaluation of nocturnal GH secretion rarely is necessary to make the diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/5/82?source=see_link&amp;anchor=H11#H11\">",
"     \"Diagnosis of growth hormone deficiency in children\", section on 'GH stimulation tests'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Recognition of GH deficiency in adults is more difficult because slow growth rate is not available as a marker. Recognition depends upon having clinical suspicion related to medical history (",
"    <a class=\"graphic graphic_table graphicRef77239 \" href=\"mobipreview.htm?0/8/137\">",
"     table 1",
"    </a>",
"    ). Adults with GH deficiency may have features of metabolic syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31607/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. Diagnosis of GH deficiency in adults requires evidence of other hypothalamic-pituitary hormone deficiencies and use of the insulin tolerance test and (one other stimulation test) with a peak response less than or equal to 5",
"    <span class=\"nowrap\">",
"     ng/mL.",
"    </span>",
"    Testing with arginine GHRH can be used with a peak GH response &le;16",
"    <span class=\"nowrap\">",
"     ng/dL.",
"    </span>",
"    However, the diagnosis of GHD can be missed in patients with abnormal hypothalamic function but preserved pituitary function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Standard therapy for GH deficiency is synthetic recombinant human GH. The dose in children is 0.15 to 0.3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per week divided into daily doses and administered subcutaneously in the evening. Lower doses are used in adults; women require a higher dose than do men [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31607/abstract/18,39\">",
"     18,39",
"    </a>",
"    ]. Each dose produces a pharmacologic level of GH for approximately 12 hours.",
"   </p>",
"   <p>",
"    The growth rate in children who are placed on GH therapy typically increases to above normal for one to three years and then slows to normal velocity.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The response is blunted in patients who have had total body irradiation. During a five-year period of GH therapy in patients after total body irradiation, height improved by 1.1 standard deviation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/55/31607/abstract/40\">",
"       40",
"      </a>",
"      ]. In contrast, GH therapy in children with idiopathic GH deficiency resulted in a growth response of 1.1 standard deviation within the first year of GH therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/55/31607/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      GH therapy after medulloblastoma and craniospinal irradiation improved adult height but did not improve spinal growth [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/55/31607/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation of the growth response and adjustment of GH dose should occur every four to six months and includes measurement of height, weight, and arm span. Arm span is a surrogate measure of height, particularly in patients in whom height measurement may not fully reflect body growth (eg, those with scoliosis or history of spinal radiation).",
"   </p>",
"   <p>",
"    GH dose can be increased as weight gain occurs to maintain a stable dose per kilogram of body weight. Serum IGF-1 measurements are recommended yearly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31607/abstract/43\">",
"     43",
"    </a>",
"    ]. Alternatively, after two years of catch-up growth has occurred, GH dose adjustment can be done on the basis of IGF titration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31607/abstract/44\">",
"     44",
"    </a>",
"    ]. In childhood cancer survivors, GH therapy should be targeted to achieve a serum IGF-1 level that is near the mean value for age.",
"   </p>",
"   <p>",
"    If IGF-1 increases above the upper limits of normal for age and gender, the GH dose should be decreased. In the unlikely event that tumor recurrence or new tumor is identified, GH therapy should be discontinued.",
"   </p>",
"   <p>",
"    Evaluation of pubertal stage and screening for development of additional endocrinopathies (thyroid, ACTH) should be performed at least annually. Magnetic resonance imaging (MRI) of the head should be repeated as clinically indicated. Even with GH therapy, some childhood cancer survivors do not grow as well as expected, suggesting that other factors, such as thyroid hormone deficiency, may be present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;GH treatment in children usually is safe. Adverse effects include slipped capital femoral epiphysis, pancreatitis, benign intracranial hypertension (pseudotumor cerebri), and carpal tunnel syndrome (",
"    <a class=\"graphic graphic_table graphicRef79365 \" href=\"mobipreview.htm?21/26/21931\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31607/abstract/45\">",
"     45",
"    </a>",
"    ]. Most adverse effects occur soon after therapy is initiated and probably are caused by sodium and water retention. An increase in the growth and pigmentation of nevi also has been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31607/abstract/46\">",
"     46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/0/14345?source=see_link&amp;anchor=H10#H10\">",
"     \"Treatment of growth hormone deficiency in children\", section on 'Adverse effects'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/42/23209?source=see_link\">",
"     \"Slipped capital femoral epiphysis (SCFE)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Any patient identified with GH deficiency should be evaluated for possible ACTH deficiency and for central hypothyroidism. If ACTH is deficient, adequate cortisol therapy should be started prior to GH or thyroid therapy. Patients with GH deficiency who have partial or total ACTH deficiency and are receiving suboptimal cortisol or cortisone replacement may be at risk of developing symptoms of cortisol deficiency when GH therapy is initiated. This is due to the inhibitory effect of growth hormone on 11-beta-hydroxysteroid dehydrogenase type 1, the enzyme that converts cortisone to cortisol [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31607/abstract/47\">",
"     47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/16/38151?source=see_link\">",
"     \"ACTH deficiency in survivors of childhood cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    GH therapy does not appear to increase the risk of brain tumor recurrence as demonstrated by the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a retrospective study of children who received radiotherapy for brain tumors, those who received GH therapy (n = 180) were compared with those who did not (n = 891) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/55/31607/abstract/48\">",
"       48",
"      </a>",
"      ]. The relative risk of recurrence of brain tumor and mortality were decreased in the GH treatment group (0.6 for recurrence and 0.5 for mortality). However, the relative risk of mortality increased with time after the first GH treatment, indicating a need for continued surveillance.",
"     </li>",
"     <li>",
"      In a retrospective review of 1038 patients with brain tumors who received growth hormone therapy, recurrence-free survival rates were 63, 69, 71, 89, and 92 percent in patients with craniopharyngiomas, glial tumors, germinomas, ependymomas, and medulloblastomas, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/55/31607/abstract/49\">",
"       49",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Childhood cancer survivors who were treated with GH may have a small increase in risk of developing second neoplasms. This was illustrated in a retrospective cohort multicenter study of 14,108 patients from the Childhood Cancer Survivor Study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31607/abstract/50\">",
"     50",
"    </a>",
"    ]. Survivors who received GH therapy were more likely to develop a second neoplasm than those who did not receive GH therapy (RR 2.15, 95% CI 1.33 to 3.47). Meningioma was the most common tumor, occurring in 9 of the 20 GH treated patients who developed second neoplasms.",
"   </p>",
"   <p>",
"    In contrast, in a study from a single center in England of patients with brain tumors who received cranial irradiation, there was no difference in the risk of developing recurrent or secondary neoplasm in patients treated with GH therapy compared with matched control patients who did not receive GH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31607/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In childhood cancer survivors, growth failure is a common complication and can be caused by a variety of different causes (see",
"    <a class=\"local\" href=\"#H2\">",
"     'Differential diagnosis for growth failure'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Growth hormone (GH) deficiency is a well-documented cause of poor growth in childhood cancer survivors, particularly after cranial irradiation.",
"     </li>",
"     <li>",
"      GH deficiency is more likely to occur in patients who received cranial radiation doses greater than 24 Gy, and who are younger at the time of radiation. GH deficiency also can be associated with chemotherapy alone, but at a much lower rate. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Cranial irradiation and chemotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The possibility of GH deficiency should be considered in children with a slow growth rate and a medical history that puts them \"at risk\" for GH deficiency. Further testing includes measurement of serum IGF-1 and IGFBP3, and bone age.",
"     </li>",
"     <li>",
"      The diagnosis of GH deficiency is generally based upon a combination of a history of cranial or total body irradiation, slow growth rate, normal weight gain, the absence of any intercurrent illness, delayed bone maturation, levels of serum IGF-1 and IGFBP3 lower than one standard deviation below the mean for age, and peak stimulated GH level less than 10",
"      <span class=\"nowrap\">",
"       ng/mL.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The treatment for GH deficiency in childhood cancer survivors is the same as used in patients with other causes of GH deficiency. Recombinant GH is administered as a standard dose for children of 0.15 to 0.3",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per week divided into daily doses and given subcutaneously in the evening. Growth should be monitored every four to six months. GH dose is adjusted based upon the patient's response and is targeted to a serum IGF-1 level that is at the mean value for age. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31607/abstract/1\">",
"      Yeung SC, Chiu AC, Vassilopoulou-Sellin R, Gagel RF. The endocrine effects of nonhormonal antineoplastic therapy. Endocr Rev 1998; 19:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31607/abstract/2\">",
"      Sklar CA. Growth and neuroendocrine dysfunction following therapy for childhood cancer. Pediatr Clin North Am 1997; 44:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31607/abstract/3\">",
"      Ogilvy-Stuart AL, Shalet SM. Growth and puberty after growth hormone treatment after irradiation for brain tumours. Arch Dis Child 1995; 73:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31607/abstract/4\">",
"      Constine LS, Woolf PD, Cann D, et al. Hypothalamic-pituitary dysfunction after radiation for brain tumors. N Engl J Med 1993; 328:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31607/abstract/5\">",
"      Clarson CL, Del Maestro RF. Growth failure after treatment of pediatric brain tumors. Pediatrics 1999; 103:E37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31607/abstract/6\">",
"      Collet-Solberg PF, Sernyak H, Satin-Smith M, et al. Endocrine outcome in long-term survivors of low-grade hypothalamic/chiasmatic glioma. Clin Endocrinol (Oxf) 1997; 47:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31607/abstract/7\">",
"      Perkins JL, Kunin-Batson AS, Youngren NM, et al. Long-term follow-up of children who underwent hematopoeitic cell transplant (HCT) for AML or ALL at less than 3 years of age. Pediatr Blood Cancer 2007; 49:958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31607/abstract/8\">",
"      Shalitin S, Phillip M, Stein J, et al. Endocrine dysfunction and parameters of the metabolic syndrome after bone marrow transplantation during childhood and adolescence. Bone Marrow Transplant 2006; 37:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31607/abstract/9\">",
"      Rutter MM, Rose SR. Long-term endocrine sequelae of childhood cancer. Curr Opin Pediatr 2007; 19:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31607/abstract/10\">",
"      Merchant TE, Rose SR, Bosley C, et al. Growth hormone secretion after conformal radiation therapy in pediatric patients with localized brain tumors. J Clin Oncol 2011; 29:4776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31607/abstract/11\">",
"      Lam KS, Tse VK, Wang C, et al. Effects of cranial irradiation on hypothalamic-pituitary function--a 5-year longitudinal study in patients with nasopharyngeal carcinoma. Q J Med 1991; 78:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31607/abstract/12\">",
"      Rose SR, Lustig RH, Pitukcheewanont P, et al. Diagnosis of hidden central hypothyroidism in survivors of childhood cancer. J Clin Endocrinol Metab 1999; 84:4472.",
"     </a>",
"    </li>",
"    <li>",
"     Rose SR. Neuroendocrine basis for insufficient growth hormone and its assessment. In: Frontiers Paediatric Neuroendocrinology, Savage MO, Bourguignon JP, Grossman AB (Eds), Blackwell Scientific Publications, Oxford, England 1994. p.149.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31607/abstract/14\">",
"      Vuagnat BA, Pierroz DD, Lalaoui M, et al. Evidence for a leptin-neuropeptide Y axis for the regulation of growth hormone secretion in the rat. Neuroendocrinology 1998; 67:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31607/abstract/15\">",
"      Bluet-Pajot MT, Epelbaum J, Gourdji D, et al. Hypothalamic and hypophyseal regulation of growth hormone secretion. Cell Mol Neurobiol 1998; 18:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31607/abstract/16\">",
"      Rose SR, Municchi G. Six-hour and four-hour nocturnal sampling for growth hormone. J Pediatr Endocrinol Metab 1999; 12:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31607/abstract/17\">",
"      Pincus SM, Veldhuis JD, Rogol AD. Longitudinal changes in growth hormone secretory process irregularity assessed transpubertally in healthy boys. Am J Physiol Endocrinol Metab 2000; 279:E417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31607/abstract/18\">",
"      Meling TR, Nylen ES. Growth hormone deficiency in adults: a review. Am J Med Sci 1996; 311:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31607/abstract/19\">",
"      Darendeliler F, Livesey EA, Hindmarsh PC, Brook CG. Growth and growth hormone secretion in children following treatment of brain tumours with radiotherapy. Acta Paediatr Scand 1990; 79:950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31607/abstract/20\">",
"      Toogood AA, Ryder WD, Beardwell CG, Shalet SM. The evolution of radiation-induced growth hormone deficiency in adults is determined by the baseline growth hormone status. Clin Endocrinol (Oxf) 1995; 43:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31607/abstract/21\">",
"      Lannering B, Rosberg S, Marky I, et al. Reduced growth hormone secretion with maintained periodicity following cranial irradiation in children with acute lymphoblastic leukaemia. Clin Endocrinol (Oxf) 1995; 42:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31607/abstract/22\">",
"      Darzy KH, Pezzoli SS, Thorner MO, Shalet SM. The dynamics of growth hormone (GH) secretion in adult cancer survivors with severe GH deficiency acquired after brain irradiation in childhood for nonpituitary brain tumors: evidence for preserved pulsatility and diurnal variation with increased secretory disorderliness. J Clin Endocrinol Metab 2005; 90:2794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31607/abstract/23\">",
"      Shalet SM. Radiation and pituitary dysfunction. N Engl J Med 1993; 328:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31607/abstract/24\">",
"      Darzy KH, Murray RD, Gleeson HK, et al. The impact of short-term fasting on the dynamics of 24-hour growth hormone (GH) secretion in patients with severe radiation-induced GH deficiency. J Clin Endocrinol Metab 2006; 91:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31607/abstract/25\">",
"      O��uz A, Pinarli FG, Karadeniz C, et al. Late effects of treatment on growth in childhood non-Hodgkin's lymphoma. Leuk Lymphoma 2006; 47:1283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31607/abstract/26\">",
"      Oberfield SE, Allen JC, Pollack J, et al. Long-term endocrine sequelae after treatment of medulloblastoma: prospective study of growth and thyroid function. J Pediatr 1986; 108:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31607/abstract/27\">",
"      Shalet SM, Price DA, Beardwell CG, et al. Normal growth despite abnormalities of growth hormone secretion in children treated for acute leukemia. J Pediatr 1979; 94:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31607/abstract/28\">",
"      Brennan BM, Rahim A, Mackie EM, et al. Growth hormone status in adults treated for acute lymphoblastic leukaemia in childhood. Clin Endocrinol (Oxf) 1998; 48:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31607/abstract/29\">",
"      Sklar CA. Growth and pubertal development in survivors of childhood cancer. Pediatrician 1991; 18:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31607/abstract/30\">",
"      Cheuk DK, Billups CA, Martin MG, et al. Prognostic factors and long-term outcomes of childhood nasopharyngeal carcinoma. Cancer 2011; 117:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31607/abstract/31\">",
"      Brauner R, Malandry F, Rappaport R, et al. Growth and endocrine disorders in optic glioma. Eur J Pediatr 1990; 149:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31607/abstract/32\">",
"      Mulder RL, Kremer LC, van Santen HM, et al. Prevalence and risk factors of radiation-induced growth hormone deficiency in childhood cancer survivors: a systematic review. Cancer Treat Rev 2009; 35:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31607/abstract/33\">",
"      Haddy TB, Mosher RB, Nunez SB, Reaman GH. Growth hormone deficiency after chemotherapy for acute lymphoblastic leukemia in children who have not received cranial radiation. Pediatr Blood Cancer 2006; 46:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31607/abstract/34\">",
"      Rose SR, Schreiber RE, Kearney NS, et al. Hypothalamic dysfunction after chemotherapy. J Pediatr Endocrinol Metab 2004; 17:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31607/abstract/35\">",
"      Brouwer CA, Gietema JA, Kamps WA, et al. Changes in body composition after childhood cancer treatment: impact on future health status--a review. Crit Rev Oncol Hematol 2007; 63:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31607/abstract/36\">",
"      Cook DM, Rose SR. A review of guidelines for use of growth hormone in pediatric and transition patients. Pituitary 2012; 15:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31607/abstract/37\">",
"      Taskinen M, Lipsanen-Nyman M, Tiitinen A, et al. Insufficient growth hormone secretion is associated with metabolic syndrome after allogeneic stem cell transplantation in childhood. J Pediatr Hematol Oncol 2007; 29:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31607/abstract/38\">",
"      Follin C, Thil&eacute;n U, Ahr&eacute;n B, Erfurth EM. Improvement in cardiac systolic function and reduced prevalence of metabolic syndrome after two years of growth hormone (GH) treatment in GH-deficient adult survivors of childhood-onset acute lymphoblastic leukemia. J Clin Endocrinol Metab 2006; 91:1872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31607/abstract/39\">",
"      Amato G, Izzo G, La Montagna G, Bellastella A. Low dose recombinant human growth hormone normalizes bone metabolism and cortical bone density and improves trabecular bone density in growth hormone deficient adults without causing adverse effects. Clin Endocrinol (Oxf) 1996; 45:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31607/abstract/40\">",
"      Bakker B, Oostdijk W, Geskus RB, et al. Growth hormone (GH) secretion and response to GH therapy after total body irradiation and haematopoietic stem cell transplantation during childhood. Clin Endocrinol (Oxf) 2007; 67:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31607/abstract/41\">",
"      Land C, Blum WF, Stabrey A, Schoenau E. Seasonality of growth response to GH therapy in prepubertal children with idiopathic growth hormone deficiency. Eur J Endocrinol 2005; 152:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31607/abstract/42\">",
"      Ciaccio M, Gil S, Guercio G, et al. Effectiveness of rhGH treatment on adult height in GH-deficient childhood survivors of medulloblastoma. Horm Res Paediatr 2010; 73:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31607/abstract/43\">",
"      Growth Hormone Research Society. Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: summary statement of the GH Research Society. GH Research Society. J Clin Endocrinol Metab 2000; 85:3990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31607/abstract/44\">",
"      Cohen P, Rogol AD, Howard CP, et al. Insulin growth factor-based dosing of growth hormone therapy in children: a randomized, controlled study. J Clin Endocrinol Metab 2007; 92:2480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31607/abstract/45\">",
"      Blethen SL, Allen DB, Graves D, et al. Safety of recombinant deoxyribonucleic acid-derived growth hormone: The National Cooperative Growth Study experience. J Clin Endocrinol Metab 1996; 81:1704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31607/abstract/46\">",
"      Bourguignon JP, Pi&eacute;rard GE, Ernould C, et al. Effects of human growth hormone therapy on melanocytic naevi. Lancet 1993; 341:1505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31607/abstract/47\">",
"      Toogood AA, Taylor NF, Shalet SM, Monson JP. Modulation of cortisol metabolism by low-dose growth hormone replacement in elderly hypopituitary patients. J Clin Endocrinol Metab 2000; 85:1727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31607/abstract/48\">",
"      Swerdlow AJ, Reddingius RE, Higgins CD, et al. Growth hormone treatment of children with brain tumors and risk of tumor recurrence. J Clin Endocrinol Metab 2000; 85:4444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31607/abstract/49\">",
"      Darendeliler F, Karagiannis G, Wilton P, et al. Recurrence of brain tumours in patients treated with growth hormone: analysis of KIGS (Pfizer International Growth Database). Acta Paediatr 2006; 95:1284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31607/abstract/50\">",
"      Ergun-Longmire B, Mertens AC, Mitby P, et al. Growth hormone treatment and risk of second neoplasms in the childhood cancer survivor. J Clin Endocrinol Metab 2006; 91:3494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31607/abstract/51\">",
"      Mackenzie S, Craven T, Gattamaneni HR, et al. Long-term safety of growth hormone replacement after CNS irradiation. J Clin Endocrinol Metab 2011; 96:2756.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6238 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-203.80.222.8-3384FBAA07-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_55_31607=[""].join("\n");
var outline_f30_55_31607=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DIFFERENTIAL DIAGNOSIS FOR GROWTH FAILURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      REGULATION OF GROWTH HORMONE SECRETION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      GROWTH HORMONE DEFICIENCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Cranial irradiation and chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H111022779\">",
"      - Cranial irradiation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H111022788\">",
"      - Chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Monitoring",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6238\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6238|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?39/2/39968\" title=\"figure 1\">",
"      Growth in childhood cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6238|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?0/8/137\" title=\"table 1\">",
"      GH evaluation cancer survivors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?21/26/21931\" title=\"table 2\">",
"      Potential adverse effects of GH therapy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/16/38151?source=related_link\">",
"      ACTH deficiency in survivors of childhood cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/27/4538?source=related_link\">",
"      Bone problems in childhood cancer patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/38/9833?source=related_link\">",
"      Causes of hypopituitarism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/18/10537?source=related_link\">",
"      Causes of short stature",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/22/37226?source=related_link\">",
"      Complications of cranial irradiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/5/82?source=related_link\">",
"      Diagnosis of growth hormone deficiency in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/7/7286?source=related_link\">",
"      Endocrine surveillance in childhood cancer survivors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/19/39223?source=related_link\">",
"      Growth failure after childhood cancer: Role of hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/30/25059?source=related_link\">",
"      Hypothalamic-pituitary axis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/1/43030?source=related_link\">",
"      Physiology of growth hormone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/42/23209?source=related_link\">",
"      Slipped capital femoral epiphysis (SCFE)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/0/14345?source=related_link\">",
"      Treatment of growth hormone deficiency in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_55_31608="Intestinal atresia";
var content_f30_55_31608=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Intestinal atresia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/55/31608/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/55/31608/contributors\">",
"     David E Wesson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/55/31608/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/55/31608/contributors\">",
"     Joseph A Garcia-Prats, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/55/31608/contributors\">",
"     William J Klish, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/55/31608/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/55/31608/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/55/31608/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;An atresia is a complete congenital obstruction of the lumen of a hollow viscus. Intestinal atresia is one of the most frequent causes of bowel obstruction in the newborn and can occur at any point in the gastrointestinal tract. The ileum is the most commonly affected site.",
"   </p>",
"   <p>",
"    The outcome of intestinal atresia following surgical repair is very good. In general, morbidity and mortality depend upon associated medical conditions such as prematurity or cystic fibrosis, other congenital anomalies, the complexity of the lesion, and surgical complications.",
"   </p>",
"   <p>",
"    Atresia and stenosis of the small and large intestine are reviewed here. Esophageal atresia and anorectal malformations, including rectal atresia, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/27/29114?source=see_link&amp;anchor=H16#H16\">",
"     \"Congenital anomalies of the intrathoracic airways and tracheoesophageal fistula\", section on 'Tracheoesophageal fistula and esophageal atresia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/63/15354?source=see_link&amp;anchor=H15#H15\">",
"     \"Constipation in children: Etiology and diagnosis\", section on 'Other causes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INCIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common site of intestinal atresia is the small intestine (jejunum and ileum). The incidence of jejunal and ileal atresia ranges from one in 1500 to 12,000 births [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31608/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Duodenal atresia occurs in one in 10,000 to 40,000 births. Approximately 30 percent of infants with duodenal atresia have a chromosomal anomaly, primarily Down syndrome. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/15/26874?source=see_link\">",
"     \"Clinical features and diagnosis of Down syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The colon is the least affected site of atresia and accounts for 7 to 10 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31608/abstract/2\">",
"     2",
"    </a>",
"    ]. The incidence is approximately one in 40,000 live births.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intestinal atresia has been classified into four types based upon their anatomic characteristics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31608/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. Type III is the most common, and type I is the least common form&nbsp;(",
"    <a class=\"graphic graphic_figure graphicRef64916 \" href=\"mobipreview.htm?21/59/22451\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31608/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Type I",
"      </strong>",
"      &mdash; The lumen is obstructed by an intact diaphragm or membrane composed of mucosa and submucosa. The muscularis and serosa remain intact, resulting in no discontinuity in the bowel. There is no external evidence of obstruction apart from a decrease in the diameter of the bowel distal to the lesion. If the membrane stretches into the distal bowel, it takes the shape of a windsock.",
"     </li>",
"     <li>",
"      <strong>",
"       Type II",
"      </strong>",
"      &mdash; An obvious gap in bowel continuity occurs. The proximal and distal segments are connected by a short fibrous band.",
"     </li>",
"     <li>",
"      <strong>",
"       Type III",
"      </strong>",
"      &mdash; This type is further subdivided into types A and B.",
"      <br/>",
"      <br/>",
"      In type IIIA, a gap in bowel continuity occurs similar to type II, but no tissue connects the blind ends. There is usually an associated V-shaped gap in the mesentery.",
"      <br/>",
"      <br/>",
"      Type IIIB consists of proximal small bowel atresia, absence of the mid-small bowel that is normally supplied by the distal superior mesenteric artery, and a large gap in the small bowel mesentery. The small bowel distal to the atresia is foreshortened and coiled like an apple peel. It receives its blood supply from the ileocolic, right colic, or inferior mesenteric artery. Because of its characteristic appearance, type IIIB is also known as an apple peel or Christmas tree deformity.",
"     </li>",
"     <li>",
"      <strong>",
"       Type IV",
"      </strong>",
"      &mdash; Type IV is composed of multiple type II or IIIA atresias; these appear like a string of sausages. The bowel may also be foreshortened.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interruption of the normal development of the gastrointestinal tract may result in intestinal atresia. The mechanism varies with the segment of bowel that is affected. Thus, it is helpful to briefly review the derivation of portions of the gastrointestinal tract. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/15/41205?source=see_link\">",
"     \"Overview of the development of the gastrointestinal tract\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The gastrointestinal tract is formed from derivatives of the embryonic foregut, midgut, and hindgut. The following structures are derivatives of these segments:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Foregut &mdash; mouth and pharynx, esophagus, stomach, and first one-third of the duodenum",
"     </li>",
"     <li>",
"      Midgut &mdash; second two-thirds of the duodenum, small intestine, ascending colon, and two-thirds of the transverse colon",
"     </li>",
"     <li>",
"      Hindgut &mdash; Distal one-third of the transverse colon, descending colon, rectum and anus",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Duodenal atresia",
"    </span>",
"    &nbsp;&mdash;&nbsp;During early gestation (weeks six and seven), portions of the intestinal tract become occluded as the endodermal epithelium proliferates. Patency is restored as recanalization occurs during weeks eight to ten. Duodenal atresia is thought to result from failure of the bowel to recanalize during this period.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Jejunal and ileal atresia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Jejunal",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ileal atresia typically is an acquired lesion thought to result from vascular disruption leading to ischemic necrosis of the fetal intestine. Because the fetal bowel is sterile, the necrotic tissue is resorbed, leaving blind proximal and distal ends, often with a gap in the mesentery. This type of atresia has been reproduced in experimental animals by ligation of mesenteric blood vessels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31608/abstract/3,7,8\">",
"     3,7,8",
"    </a>",
"    ]. Causes of the vascular disruption in the human fetus include segmental or midgut volvulus, intussusception, internal hernia, and interruption of the segmental mesenteric blood supply [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31608/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Maternal use of vasoconstrictive medications may contribute to interruption of mesenteric blood flow. This was illustrated by a case-control study in which combined exposure to vasoconstrictive drugs (including methylenedioxymethamphetamine,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/8/20613?source=see_link\">",
"     pseudoephedrine",
"    </a>",
"    , and ephedrine) and cigarette smoking in the first trimester of pregnancy nearly tripled the risk of small intestinal atresia (odds ratio 2.8) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31608/abstract/10\">",
"     10",
"    </a>",
"    ]. The risk was increased 4.2 times in women who used vasoconstrictive drugs and smoked &ge;20 cigarettes per day.",
"   </p>",
"   <p>",
"    Inherited thrombophilia leading to spontaneous thrombosis may play a role in some cases. In one study, the factor V Leiden mutation and the RR subtype of the R353Q polymorphism, both risk factors for thrombosis, occurred more often in newborns with intestinal atresia than in the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31608/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Gastroschisis is frequently complicated by intestinal atresias, 11 percent of cases in one series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31608/abstract/12\">",
"     12",
"    </a>",
"    ]. The extent ranges from a simple localized lesion to the rare occurrence of atresia of the entire herniated bowel [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31608/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. The latter appears to be due to ischemic necrosis from constriction of the umbilical ring or volvulus of the herniated bowel [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31608/abstract/14\">",
"     14",
"    </a>",
"    ]. As the necrotic bowel is resorbed, the proximal bowel seals off, forming an atresia that is usually in the proximal jejunum. The abdominal wall defect may also close as the herniated bowel disappears. The prognosis of this variant is poor because the loss of almost the entire small bowel results in severe short gut syndrome. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/40/35464?source=see_link\">",
"     \"Obstetrical management of gastroschisis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Type IIIB or apple peel atresia may result from a volvulus of all or part of the midgut during gestation. As a result, much of the gut supplied by the superior mesenteric artery disappears, leaving a high jejunal or occasionally even a distal duodenal atresia. The distal ileum winds around a thin vascular stalk, which usually consists of the left branch of the ileocolic artery. A large gap in the mesentery is present along with intestinal malrotation and a microcolon. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/48/20232?source=see_link\">",
"     \"Intestinal malrotation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although most cases of intestinal atresia are sporadic, familial cases of apple peel atresia have been reported, suggesting a genetic component [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31608/abstract/15\">",
"     15",
"    </a>",
"    ]. Multiple atresias also have been reported to recur in families [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31608/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Colonic atresia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The colon is a less frequent site of atresia. The mechanism is unknown, but most authorities believe it is the same as for small bowel atresia. Colonic atresia may occur in combination with Hirschsprung disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31608/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most infants with intestinal atresia are born at or near term. Those with duodenal atresia or other proximal obstruction tend to be small for gestational age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31608/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Intestinal obstruction typically presents with abdominal distension except in the most proximal lesions. Vomiting usually begins in the first 24 to 48 hours after birth.",
"   </p>",
"   <p>",
"    Presentation may be delayed for days or weeks in infants with partial obstruction due to stenosis. The diagnosis may not be suspected until the baby has experienced multiple episodes of vomiting and abdominal distension.",
"   </p>",
"   <p>",
"    Intestinal obstruction increases the enterohepatic circulation of bilirubin and often results in jaundice. Serum bilirubin concentration frequently is higher with small than with large bowel obstruction. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/3/39992?source=see_link\">",
"     \"Pathogenesis and etiology of unconjugated hyperbilirubinemia in the newborn\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Duodenal atresia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants with duodenal atresia or stenosis typically have gastric distension and vomiting that may be bilious. Affected infants may pass meconium.",
"   </p>",
"   <p>",
"    Duodenal atresia is an isolated finding in one-third to one-half of cases. However, it is often associated with other malformations, including gastrointestinal (biliary atresia, agenesis of the gall bladder), cardiac, renal, and vertebral anomalies. As an example, in a series of newborns undergoing surgery for gastrointestinal malformations, echocardiography detected congenital heart disease in six of 20 infants with duodenal atresia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31608/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Approximately 24 to 28 percent of newborns with duodenal atresia or stenosis have Down syndrome. Conversely, approximately 2.5 percent of patients with Down syndrome have duodenal atresia or stenosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31608/abstract/2,21\">",
"     2,21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/15/26874?source=see_link\">",
"     \"Clinical features and diagnosis of Down syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Jejunal and ileal atresia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Affected infants typically develop abdominal distension and vomiting within the first two days after birth. Emesis usually is bilious. Most infants with bowel obstruction fail to pass meconium. However, meconium may remain in the distal bowel beyond the obstruction. As a result, newborns with jejunal or ileal atresia may pass meconium.",
"   </p>",
"   <p>",
"    Most jejunoileal atresias occur in otherwise normal newborns, although some cases are associated with other malformations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31608/abstract/22\">",
"     22",
"    </a>",
"    ]. Jejunal or ileal atresia may also occur in meconium ileus, which is nearly always due to cystic fibrosis. In the series noted above, 10 of 83 infants with jejunal or ileal atresia had cystic fibrosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31608/abstract/22\">",
"     22",
"    </a>",
"    ]. In fetuses with cystic fibrosis, inspissated meconium may cause a localized volvulus that results in ischemic necrosis; the necrotic bowel is resorbed and seals off, forming an atresia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/49/28442?source=see_link\">",
"     \"Cystic fibrosis: Clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Colonic atresia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Like other types of bowel obstruction, colonic atresia presents with abdominal distension and bilious vomiting. Because the obstruction is low, symptoms may appear later than with more proximal lesions, although usually within the first three days after birth.",
"   </p>",
"   <p>",
"    Colonic atresia typically affects otherwise normal newborns. In rare cases, it may be associated with gastroschisis, skeletal abnormalities, other intestinal atresias, and Hirschsprung disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31608/abstract/18,23\">",
"     18,23",
"    </a>",
"    ]. Cases have been reported with congenital varicella syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31608/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     PRENATAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although most infants with bowel obstruction present in the early postnatal period, intestinal atresias often are detected by prenatal ultrasound examination. This is helpful because infants can be treated promptly after birth, reducing the risk of complications of poor feeding and vomiting, including volume depletion, electrolyte imbalance, and aspiration pneumonia.",
"   </p>",
"   <p>",
"    Ultrasound findings that suggest intestinal atresia include polyhydramnios, a dilated loop of bowel, hyperechoic bowel, and ascites. Proximal atresias are more likely than distal lesions to be detected prenatally. Distal lesions usually are detected after birth.",
"   </p>",
"   <p>",
"    On prenatal ultrasound, duodenal atresia usually has the characteristic double bubble appearance that is seen on a postnatal abdominal radiograph. This finding is due to dilation of the stomach and the first part of the duodenum.",
"   </p>",
"   <p>",
"    Polyhydramnios is often associated with proximal bowel obstruction, and occurs in more than 50 percent of patients with duodenal atresia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31608/abstract/25\">",
"     25",
"    </a>",
"    ]. Conversely, 15 to 20 percent of cases of polyhydramnios are associated with fetal intestinal obstruction.",
"   </p>",
"   <p>",
"    Prenatal ultrasound signs of jejunal and ileal atresia may include ascites, dilated bowel loops, and increased bowel echogenicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31608/abstract/26-28\">",
"     26-28",
"    </a>",
"    ]. Lesions that are detected usually are located in the proximal jejunum because they result in more severe dilation of the proximal bowel due to continuing fetal swallowing of amniotic fluid which outpaces intestinal absorption [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31608/abstract/29\">",
"     29",
"    </a>",
"    ]. Ileal or colonic atresias are recognized before birth less often.",
"   </p>",
"   <p>",
"    The accuracy of prenatal ultrasound screening to detect bowel atresias was evaluated in a large series of infants who had prenatal scans and postnatal follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31608/abstract/30\">",
"     30",
"    </a>",
"    ]. Suspected fetal small bowel obstruction was confirmed postnatally in eight cases. These consisted of jejunal atresia (four cases, including two with cystic fibrosis), meconium ileus with cystic fibrosis (two cases), apple peel deformity (one case), and malrotation with jejunal obstruction (one case). A dilated loop of bowel with enlargement during the third trimester led to detection in seven cases. Ascites and increased amniotic fluid volume led to identification of the other case. In the same series, only two of 11 cases of suspected large bowel obstruction were confirmed postnatally. Conversely, only two of 26 cases of large bowel obstruction diagnosed postnatally were identified by prenatal ultrasound.",
"   </p>",
"   <p>",
"    Prenatal ultrasonography is not always accurate, and plain radiographs and contrast examinations should be obtained after birth in nearly all cases to confirm the diagnosis. Duodenal atresia is particularly difficult to distinguish from choledochal cyst by antenatal ultrasonography.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     POSTNATAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intestinal atresia should be suspected in a newborn with signs of intestinal obstruction. These include abdominal distension, bilious vomiting, and failure to pass meconium.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;A complete maternal history should be obtained. This should include family history, medications, and pregnancy complications, such as polyhydramnios. Results of prenatal ultrasound examinations should be obtained.",
"   </p>",
"   <p>",
"    The infant's gestational age should be recorded. The history should include the timing of onset of abdominal distention and vomiting, if the emesis was bilious or nonbilious, whether meconium was passed and when, and whether the infant was fed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;A complete physical examination should be performed, including an assessment of severity of illness. The infant should be evaluated for respiratory compromise and for signs of volume depletion (eg, dry mucus membranes, poor skin turgor, and sunken fontanelle).",
"   </p>",
"   <p>",
"    Congenital anomalies should be documented, including signs of chromosomal abnormalities such as Down syndrome. The presence of jaundice should be noted.",
"   </p>",
"   <p>",
"    The appearance of the abdomen may suggest the location of the atresia. If the obstruction is distal, the abdomen is often markedly distended with visible or palpable loops of bowel. Proximal obstruction may result in little distention.",
"   </p>",
"   <p>",
"    The abdomen should be palpated to detect the presence of a mass. Abdominal tenderness may indicate peritonitis. The presence or absence of bowel sounds should be noted.",
"   </p>",
"   <p>",
"    The perineum should be examined. The location and patency of the anus should be noted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of neonates who present with symptoms and signs of intestinal obstruction includes malrotation with volvulus, Hirschsprung disease, and meconium ileus, in addition to intestinal atresia (",
"    <a class=\"graphic graphic_table graphicRef66065 \" href=\"mobipreview.htm?4/62/5099\">",
"     table 1",
"    </a>",
"    ). These causes usually can be distinguished by a contrast radiographs. A rectal biopsy is needed to confirm the diagnosis of Hirschsprung disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/49/28442?source=see_link\">",
"     \"Cystic fibrosis: Clinical manifestations and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/55/41848?source=see_link\">",
"     \"Congenital aganglionic megacolon (Hirschsprung disease)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Radiographic studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plain radiographs of the abdomen should be obtained all infants with signs of bowel obstruction. If intestinal obstruction was diagnosed prenatally on ultrasound, plain radiographs should be performed after birth to confirm the diagnosis. The extent of distension may suggest the site of the atresia in the proximal or distal bowel. Contrast studies of the gastrointestinal tract are often helpful in establishing the specific cause of the obstruction.",
"   </p>",
"   <p>",
"    Although some radiographic signs strongly suggest intestinal atresia (eg, the double bubble sign in duodenal atresia), additional imaging with contrast should be performed before proceeding to surgery, unless urgent intervention is indicated because of pneumoperitoneum or signs of shock or peritonitis. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Contrast radiographs'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Abdominal radiograph",
"    </span>",
"    &nbsp;&mdash;&nbsp;A supine antero-posterior and either upright, lateral decubitus or cross table lateral films should be obtained in all cases of suspected neonatal intestinal obstruction. Pneumoperitoneum usually indicates an intestinal perforation, and requires emergent laparotomy.",
"   </p>",
"   <p>",
"    Duodenal atresia causes a classic double bubble sign due to dilation of the stomach and proximal duodenum; distal gas is absent (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef73385 \" href=\"mobipreview.htm?4/61/5087\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef64334 \" href=\"mobipreview.htm?29/38/30318\">",
"     image 2",
"    </a>",
"    ). This sign may be obscured by excessive fluid in the stomach. In that case, aspiration of the stomach through a nasogastric tube and injection of 30 to 60 mL of air may confirm the diagnosis. Although duodenal atresia is the most common cause of high-grade duodenal obstruction in neonates, other problems such as malrotation with volvulus can present with similar findings on plain radiograph [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31608/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Duodenal stenosis usually causes only partial obstruction. Plain abdominal radiographs often show an air-fluid level in the duodenum.",
"   </p>",
"   <p>",
"    Duodenal atresia and stenosis may be associated with malrotation. Thus, if immediate operation is delayed because of extreme prematurity, metabolic disturbance, or another anomaly, an upper gastrointestinal contrast study should be done to rule out malrotation, which if present causes a risk for midgut volvulus. At surgery for malrotation in a neonate, intrinsic obstruction should always be excluded by passing saline or a catheter through the duodenum into the upper jejunum. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Contrast radiographs'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/48/20232?source=see_link&amp;anchor=H9#H9\">",
"     \"Intestinal malrotation\", section on 'Duodenal obstruction'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The appearance of jejunal or ileal atresia on plain abdominal radiographs typically consists of dilated loops of small bowel with air-fluid levels. The more distal the atresia, the more obvious the distention becomes.",
"   </p>",
"   <p>",
"    Intraperitoneal calcification suggests prenatal perforation of the gut and meconium peritonitis. This usually indicates meconium ileus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Contrast radiographs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The appearance of a double bubble with no distal gas on the plain abdominal film strongly suggests duodenal atresia. If this finding is present, no further radiographic study is needed prior to surgical intervention. However, if the patient is stable, some experts suggest a contrast upper gastrointestinal series even if a double bubble sign is present, because this finding occasionally occurs with other causes of high-grade duodenal obstruction, such as malrotation with volvulus. If a double bubble is not seen and distal gas is present, a contrast enema should be performed to identify the site of atresia or to identify another cause of obstruction.",
"   </p>",
"   <p>",
"    In most cases,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    can be used to perform the contrast enema. However, if obstruction is thought to be due to meconium ileus and the infant is adequately hydrated and clinically stable, use of a hypertonic agent such as meglumine diatrizoate (Gastrografin) can be both diagnostic and therapeutic.",
"   </p>",
"   <p>",
"    In cases of small bowel atresia, the contrast enema often reveals a microcolon, resulting from lack of use of this portion of the bowel. In small bowel atresia, it is not possible to reflux contrast medium into the dilated loops of more proximal bowel. A microcolon may also be present in meconium ileus. In that case, contrast medium can often be injected retrograde into the proximal dilated ileum and may demonstrate typical intraluminal filling defects caused by abnormal meconium. A contrast enema can also reveal evidence of colonic atresia or Hirschsprung disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/55/41848?source=see_link\">",
"     \"Congenital aganglionic megacolon (Hirschsprung disease)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Laboratory studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;No laboratory studies are diagnostic of intestinal atresia. However, laboratory studies that should be obtained to help assess the infant's clinical condition include complete blood count and differential, serum electrolyte concentration, BUN, and creatinine level. If sepsis is suspected, a blood culture should be obtained.",
"   </p>",
"   <p>",
"    Arterial blood gas measurements may be needed if the infant shows signs of respiratory distress. In preparation for surgery, blood type and antibody screen and coagulation studies (prothrombin time and partial thromboplastin time) should be obtained.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Other studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific studies may be required to evaluate the infant for associated congenital anomalies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31608/abstract/32\">",
"     32",
"    </a>",
"    ]. In some cases, testing should occur prior to surgery.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An echocardiogram should be performed in infants with duodenal atresia. A preoperative cardiac assessment is most important in patients with Down syndrome.",
"     </li>",
"     <li>",
"      Infants with duodenal and jejunoileal atresia should have an anterior-posterior and lateral chest radiograph to detect vertebral anomalies.",
"     </li>",
"     <li>",
"      Renal ultrasonography should be performed in infants with duodenal atresia.",
"     </li>",
"     <li>",
"      Infants with duodenal atresia and Down syndrome should have a rectal biopsy if there is any suspicion of Hirschsprung disease. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/55/41848?source=see_link\">",
"       \"Congenital aganglionic megacolon (Hirschsprung disease)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Mutation analysis for cystic fibrosis should be performed on a DNA sample obtained by buccal smear in infants with small bowel atresia and meconium plugs. If this screen does not detect a mutation causing cystic fibrosis, a sweat test should be obtained. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/49/28442?source=see_link\">",
"       \"Cystic fibrosis: Clinical manifestations and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of intestinal atresia consists of initial preoperative management followed by surgical correction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Initial management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with intestinal obstruction should have feedings withheld and a nasogastric or orogastric tube placed to suction. Intravenous access should be established and parenteral fluids should be provided. Abnormalities in fluid and electrolyte balance should be corrected. We give broad-spectrum antibiotics (",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/38/38503?source=see_link\">",
"     ampicillin",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/48/37632?source=see_link\">",
"     gentamicin",
"    </a>",
"    ) to prevent postoperative infection.",
"   </p>",
"   <p>",
"    If the infant is ill and malrotation and volvulus have been excluded, immediate surgery for intestinal atresia is not necessary. The operation can be postponed until metabolic, cardiac,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    respiratory abnormalities have been diagnosed and treated and the patient is in optimal condition. However, the risk of deferring surgery must be weighed against those of possible vomiting and aspiration, sepsis, and complications of prolonged",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/40/42628?source=see_link\">",
"     total parenteral nutrition",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Surgical approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;The surgical approach depends upon the site of the atresia. In every case, the possibility of a second or multiple atresias should be considered. With a proximal obstruction, distal atresias may be overlooked at operation, especially if they are not associated with a gap in the bowel or mesentery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Duodenal atresia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Duodenal atresia is approached through a transverse right upper quadrant incision. Duodenal atresia can also be repaired laparoscopically, but this approach has not been widely adopted. The best and safest procedure is an end-to-side or side-to-side duodenoduodenostomy. A duodenojejunostomy is also acceptable. During surgery, a small catheter should be passed into the distal bowel. Either air or saline should be injected through the entire small bowel to rule out additional stenoses or atresias.",
"   </p>",
"   <p>",
"    In cases of stenosis or atresia due to a persistent membrane, we usually perform a duodeno-duodenostomy. We do not resect the obstructing membrane because of the possibility of damaging the bile duct or pancreatic duct. However, others recommend excision of the web.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Jejunal and ileal atresia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Jejunal and ileal atresias can be approached through a transverse incision below or just above the umbilicus. Some surgeons prefer a trans-umbilical approach to minimize the scar from the incision. Primary repair usually is best. In most, a simple end-to-end or end-to-back anastomosis can be made [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31608/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients with jejunal atresia the proximal segment of bowel usually becomes dilated due to continuing peristalsis proximal to the obstruction. This dilated segment may cause technical difficulties with the anastomosis. In addition, it may lead to functional obstruction after the repair due to ineffective peristalsis, which may result because the dilation prevents apposition of the bowel mucosa as peristaltic waves pass through it and because of disturbance of coordinated muscle activity. Therefore, in order to minimize dysfunction at the site of the anastomosis, some surgeons recommend that the most dilated proximal bowel should be tapered or resected.",
"   </p>",
"   <p>",
"    Primary repair is preferred if multiple atresias are present and care is taken to preserve intestinal length. In cases with short segments between atretic lesions, it may be preferable to resect the entire section of involved bowel rather than perform multiple anastomoses, provided that this will leave an adequate length of bowel. Adequate bowel length is considered to be at least 30 cm of jejunum and ileum with an intact ileocecal sphincter, but ideally more than 75 cm. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/9/26778?source=see_link\">",
"     \"Management of the short bowel syndrome in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Small bowel atresia and gastroschisis",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several approaches to the management of small bowel atresia associated with gastroschisis. A primary repair can be performed at the time of reduction of the bowel and closure of the abdominal wall. Alternatively, surgical correction can be delayed until several weeks after repair of the gastroschisis. A third approach is to make a stoma at the time of abdominal wall repair and defer reanastomosis of the bowel until the infant is older.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Colonic atresia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary repair often is technically feasible in colonic atresia. If this approach is taken, we suggest obtaining a suction rectal biopsy prior to the primary repair, to rule out Hirschsprung disease. However, a better approach may be to exteriorize the proximal colon as a colostomy and defer anastomosis until the child is several months of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31608/abstract/34\">",
"     34",
"    </a>",
"    ]. This approach allows time for a rectal biopsy to rule out Hirschsprung disease. It may preserve bowel length by allowing the proximal colon to shrink back to a more normal size and to recover its tone. This may avoid unnecessary resection of the proximal colon and preserve its ability to absorb salt and water. Most babies thrive with a colostomy and can be discharged earlier from the hospital than with a primary repair.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Postoperative care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following surgery, intravenous hydration and nasogastric or orogastric drainage should be provided until bowel function returns. In most cases,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/40/42628?source=see_link\">",
"     total parenteral nutrition",
"    </a>",
"    (TPN) is started within 24 to 48 hours of surgery and continued until oral feeding is established, which is usually possible in three to five days.",
"   </p>",
"   <p>",
"    Most infants recover uneventfully following repair of intestinal atresia. Patients with atresia associated with meconium ileus due to cystic fibrosis require appropriate treatment. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/15/19706?source=see_link\">",
"     \"Cystic fibrosis: Overview of gastrointestinal disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/22/39274?source=see_link\">",
"     \"Cystic fibrosis: Overview of the treatment of lung disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Repair of duodenal atresia may be complicated by delayed emptying of the duodenum. Reoperation is indicated only when radiographic studies demonstrate obstruction, but should not be attempted for at least three weeks following the initial surgery. Some cases of jejunal and ileal atresia, especially types IIIB and IV, may be complicated by short bowel syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis for intestinal atresia is very good. Most of the mortality occurs in infants with medical conditions such as prematurity or respiratory distress syndrome, associated anomalies, or complications such as short gut syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31608/abstract/28,35\">",
"     28,35",
"    </a>",
"    ]. As an example, in a series of 277 newborns with intestinal atresia and stenosis treated from 1972 to 1997 in Indiana, long-term survival for duodenal atresia, jejunoileal atresia, and colonic atresia was 86, 84, and 100 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31608/abstract/10\">",
"     10",
"    </a>",
"    ]. Similar results were reported in a series of 83 patients with jejunoileal atresia and without gastroschisis born from 1976 to 1998 in the United Kingdom, with overall survival of 90 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31608/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The major causes of morbidity and mortality are short bowel syndrome and cardiac anomalies, often associated with duodenal atresia, especially in infants with Down syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31608/abstract/10\">",
"     10",
"    </a>",
"    ]. The prognosis of newborns with meconium ileus is similar to other children with cystic fibrosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/49/28442?source=see_link\">",
"     \"Cystic fibrosis: Clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The prognosis of complex atresias depends upon the length and function of the remaining bowel. Bowel function determines the required duration of TPN with its associated risks of sepsis and liver failure. Patients at especially high risk for short bowel syndrome include those with Type IV atresias and gastroschisis.",
"   </p>",
"   <p>",
"    Late operative complications include recurrent obstruction from anastomotic dysfunction, stricture, and adhesions, and are more likely to occur in complex atresias. Anastomotic dysfunction often complicates the recovery of infants with type IIIB (apple peel) atresia, who usually require prolonged TPN and may develop cholestasis and sepsis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31608/abstract/36\">",
"     36",
"    </a>",
"    ]. Despite these complications, contemporary surgical techniques and newborn intensive care have improved survival in this disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31608/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20612231\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20612535\">",
"    <span class=\"h2\">",
"     Clinical presentation and evaluation",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intestinal atresia is a congenital complete obstruction of the lumen of the intestine, is one of the most frequent causes of bowel obstruction in the newborn, and can occur at any point in the gastrointestinal tract. The ileum is the most commonly affected site, followed by the jejunum, duodenum, and colon. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Incidence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Jejunal and ileal atresias are acquired in utero, resulting from vascular disruption leading to ischemic necrosis of the fetal intestine. Causes of the vascular disruption include intestinal volvulus, intussusception, internal hernia, gastroschisis, meconium ileus, and interruption of the segmental mesenteric blood supply. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Jejunal and ileal atresia'",
"      </a>",
"      above.) &nbsp; &nbsp;",
"     </li>",
"     <li>",
"      Findings on prenatal ultrasound that suggest the possibility of intestinal atresia include polyhydramnios, dilated bowel, or increased bowel echogenicity. Duodenal atresia is suggested by the &ldquo;double bubble&rdquo; formed by the dilated proximal duodenum and stomach. Prenatal ultrasonography is not always accurate, and plain radiographs and contrast examinations should be obtained after birth to confirm the diagnosis. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Prenatal diagnosis'",
"      </a>",
"      above.) &nbsp; &nbsp;",
"     </li>",
"     <li>",
"      Infants with jejunal and ileal atresia typically present with abdominal distension and bilious vomiting, usually beginning in the first two days of life. The presentation may be delayed for days or weeks in infants with stenosis (partial obstruction) of the intestine rather than atresia. Hyperbilirubinemia is common. About 10 percent of infants with jejunal or ileal atresia have cystic fibrosis and meconium ileus. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Infants with duodenal atresia present with gastric distension and vomiting, which may or may not be bilious. About 25 percent of newborns with duodenal atresia have Down syndrome. In infants without Down syndrome, other congenital malformations are common, including gastrointestinal (biliary atresia, agenesis of the gall bladder), cardiac, renal, and vertebral anomalies. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Duodenal atresia'",
"      </a>",
"      above.) &nbsp; &nbsp; &nbsp;",
"     </li>",
"     <li>",
"      On plain abdominal film, a double bubble sign strongly suggests duodenal atresia; distal gas is absent (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef73385 \" href=\"mobipreview.htm?4/61/5087\">",
"       image 1",
"      </a>",
"      ). Jejunal or ileal atresia typically appears as dilated loops of small bowel with air-fluid levels. The bowel distension is most prominent in more distal atresias. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Abdominal radiograph'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Additional evaluation for most infants includes contrast radiographs to confirm and better define the anomaly, plain chest films for vertebral anomalies, and laboratory studies to assess the infant's clinical condition including complete blood count and differential, serum electrolyte concentration, blood urea nitrogen (BUN), and creatinine. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Laboratory studies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Additional tests to assess for associated conditions are indicated in patients with duodenal atresia (echocardiogram and renal ultrasonography), Down syndrome (rectal biopsy to evaluate for Hirschsprung disease), and meconium plugs (testing for cystic fibrosis). (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Other studies'",
"      </a>",
"      above.) &nbsp; &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20612527\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Preoperative management for an infant with intestinal atresia includes withholding feedings and placement of a nasogastric or orogastric tube to continuous suction. Intravenous access should be established, and parenteral fluids should be provided. Abnormalities in fluid and electrolyte balance should be corrected. We give broad-spectrum antibiotics (",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/38/38503?source=see_link\">",
"       ampicillin",
"      </a>",
"      and",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/48/37632?source=see_link\">",
"       gentamicin",
"      </a>",
"      ) to prevent postoperative infection. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Initial management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The surgical approach depends upon the site of the atresia. In every case, the possibility of a second or multiple atresias should be considered. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Surgical approach'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31608/abstract/1\">",
"      Best KE, Tennant PW, Addor MC, et al. Epidemiology of small intestinal atresia in Europe: a register-based study. Arch Dis Child Fetal Neonatal Ed 2012; 97:F353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31608/abstract/2\">",
"      Dalla Vecchia LK, Grosfeld JL, West KW, et al. Intestinal atresia and stenosis: a 25-year experience with 277 cases. Arch Surg 1998; 133:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31608/abstract/3\">",
"      Louw JH. Resection and end-to-end anastomosis in the management of atresia and stenosis of the small bowel. Surgery 1967; 62:940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31608/abstract/4\">",
"      Martin LW, Zerella JT. Jejunoileal atresia: a proposed classification. J Pediatr Surg 1976; 11:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31608/abstract/5\">",
"      Grosfeld JL, Ballantine TV, Shoemaker R. Operative mangement of intestinal atresia and stenosis based on pathologic findings. J Pediatr Surg 1979; 14:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31608/abstract/6\">",
"      Kao KJ, Fleischer R, Bradford WD, Woodard BH. Multiple congenital septal atresias of the intestine: histomorphologic and pathogenetic implications. Pediatr Pathol 1983; 1:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31608/abstract/7\">",
"      Tibboel D, van der Kamp AW, Molenaar JC. The effect of experimentally induced intestinal perforation at an early developmental stage. J Pediatr Surg 1981; 16:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31608/abstract/8\">",
"      Lopez de Torre B, Tovar JA, Uriarte S, Aldazabal P. The nutrition of the fetus with intestinal atresia: studies in the chick embryo model. J Pediatr Surg 1992; 27:1325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31608/abstract/9\">",
"      Kilic N, Kiristioglu I, Kirkpinar A, Dogruyol H. A very rare cause of intestinal atresia: intrauterine intussusception due to Meckel's diverticulum. Acta Paediatr 2003; 92:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31608/abstract/10\">",
"      Werler MM, Sheehan JE, Mitchell AA. Association of vasoconstrictive exposures with risks of gastroschisis and small intestinal atresia. Epidemiology 2003; 14:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31608/abstract/11\">",
"      Johnson SM, Meyers RL. Inherited thrombophilia: a possible cause of in utero vascular thrombosis in children with intestinal atresia. J Pediatr Surg 2001; 36:1146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31608/abstract/12\">",
"      Baerg J, Kaban G, Tonita J, et al. Gastroschisis: A sixteen-year review. J Pediatr Surg 2003; 38:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31608/abstract/13\">",
"      Kimble RM, Blakelock R, Cass D. Vanishing gut in infants with gastroschisis. Pediatr Surg Int 1999; 15:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31608/abstract/14\">",
"      Ogunyemi D. Gastroschisis complicated by midgut atresia, absorption of bowel, and closure of the abdominal wall defect. Fetal Diagn Ther 2001; 16:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31608/abstract/15\">",
"      Seashore JH, Collins FS, Markowitz RI, Seashore MR. Familial apple peel jejunal atresia: surgical, genetic, and radiographic aspects. Pediatrics 1987; 80:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31608/abstract/16\">",
"      Gahukamble DB, Gahukamble LD. Multiple gastrointestinal atresias in two consecutive siblings. Pediatr Surg Int 2002; 18:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31608/abstract/17\">",
"      Gahukamble DB, Adnan AR, Al-Gadi M. Atresias of the gastrointestinal tract in an inbred, previously unstudied population. Pediatr Surg Int 2002; 18:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31608/abstract/18\">",
"      Seo T, Ando H, Watanabe Y, et al. Colonic atresia and Hirschsprung's disease: importance of histologic examination of the distal bowel. J Pediatr Surg 2002; 37:E19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31608/abstract/19\">",
"      Cozzi F, Wilkinson AW. Intrauterine growth rate in relation to anorectal and oesophageal anomalies. Arch Dis Child 1969; 44:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31608/abstract/20\">",
"      Tulloh RM, Tansey SP, Parashar K, et al. Echocardiographic screening in neonates undergoing surgery for selected gastrointestinal malformations. Arch Dis Child Fetal Neonatal Ed 1994; 70:F206.",
"     </a>",
"    </li>",
"    <li>",
"     Epstein CJ. Down syndrome (Trisomy 21). In: The Metabolic and Molecular Bases of Inherited Disease, 8th, Scriver CR, Beaudet AL, Sly WS, Valle D (Eds), McGraw-Hill, New York 2001. p.1223.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31608/abstract/22\">",
"      Sweeney B, Surana R, Puri P. Jejunoileal atresia and associated malformations: correlation with the timing of in utero insult. J Pediatr Surg 2001; 36:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31608/abstract/23\">",
"      Azzie G, Craw S, Beasley SW. Colonic atresia: From suspicion to confirmation on pre-operative radiology. J Paediatr Child Health 2002; 38:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31608/abstract/24\">",
"      Sauve RS, Leung AK. Congenital varicella syndrome with colonic atresias. Clin Pediatr (Phila) 2003; 42:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31608/abstract/25\">",
"      Brantberg A, Blaas HG, Salvesen KA, et al. Fetal duodenal obstructions: increased risk of prenatal sudden death. Ultrasound Obstet Gynecol 2002; 20:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31608/abstract/26\">",
"      Phelps S, Fisher R, Partington A, Dykes E. Prenatal ultrasound diagnosis of gastrointestinal malformations. J Pediatr Surg 1997; 32:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31608/abstract/27\">",
"      Ghose I, Mason GC, Martinez D, et al. Hyperechogenic fetal bowel: a prospective analysis of sixty consecutive cases. BJOG 2000; 107:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31608/abstract/28\">",
"      Kumaran N, Shankar KR, Lloyd DA, Losty PD. Trends in the management and outcome of jejuno-ileal atresia. Eur J Pediatr Surg 2002; 12:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31608/abstract/29\">",
"      Tam PK, Nicholls G. Implications of antenatal diagnosis of small-intestinal atresia in the 1990s. Pediatr Surg Int 1999; 15:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31608/abstract/30\">",
"      Corteville JE, Gray DL, Langer JC. Bowel abnormalities in the fetus--correlation of prenatal ultrasonographic findings with outcome. Am J Obstet Gynecol 1996; 175:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31608/abstract/31\">",
"      Gilbertson-Dahdal DL, Dutta S, Varich LJ, Barth RA. Neonatal malrotation with midgut volvulus mimicking duodenal atresia. AJR Am J Roentgenol 2009; 192:1269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31608/abstract/32\">",
"      Kimble RM, Harding J, Kolbe A. Additional congenital anomalies in babies with gut atresia or stenosis: when to investigate, and which investigation. Pediatr Surg Int 1997; 12:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31608/abstract/33\">",
"      Patil VK, Kulkarni BK, Jiwane A, et al. Intestinal atresia: an end-to-end linear anastomotic technique. Pediatr Surg Int 2001; 17:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31608/abstract/34\">",
"      Watts AC, Sabharwal AJ, MacKinlay GA, Munro FD. Congenital colonic atresia: should primary anastomosis always be the goal? Pediatr Surg Int 2003; 19:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31608/abstract/35\">",
"      Escobar MA, Ladd AP, Grosfeld JL, et al. Duodenal atresia and stenosis: long-term follow-up over 30 years. J Pediatr Surg 2004; 39:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31608/abstract/36\">",
"      Festen S, Brevoord JC, Goldhoorn GA, et al. Excellent long-term outcome for survivors of apple peel atresia. J Pediatr Surg 2002; 37:61.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5863 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-61.234.146.186-A7177AF1CA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_55_31608=[""].join("\n");
var outline_f30_55_31608=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20612231\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Duodenal atresia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Jejunal and ileal atresia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Colonic atresia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Duodenal atresia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Jejunal and ileal atresia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Colonic atresia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      PRENATAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      POSTNATAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Radiographic studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Abdominal radiograph",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Contrast radiographs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Laboratory studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Other studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Initial management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Surgical approach",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Duodenal atresia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Jejunal and ileal atresia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Small bowel atresia and gastroschisis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Colonic atresia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Postoperative care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20612231\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20612535\">",
"      Clinical presentation and evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20612527\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5863\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5863|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?4/61/5087\" title=\"diagnostic image 1\">",
"      Plain radiograph of an infant with duodenal atresia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?29/38/30318\" title=\"diagnostic image 2\">",
"      Contrast study in duodenal atresia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5863|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?21/59/22451\" title=\"figure 1\">",
"      Classification of jejunoileal atresia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5863|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?4/62/5099\" title=\"table 1\">",
"      Ddx intestinal atresia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/15/26874?source=related_link\">",
"      Clinical features and diagnosis of Down syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/55/41848?source=related_link\">",
"      Congenital aganglionic megacolon (Hirschsprung disease)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/27/29114?source=related_link\">",
"      Congenital anomalies of the intrathoracic airways and tracheoesophageal fistula",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/63/15354?source=related_link\">",
"      Constipation in children: Etiology and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/49/28442?source=related_link\">",
"      Cystic fibrosis: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/15/19706?source=related_link\">",
"      Cystic fibrosis: Overview of gastrointestinal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/22/39274?source=related_link\">",
"      Cystic fibrosis: Overview of the treatment of lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/48/20232?source=related_link\">",
"      Intestinal malrotation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/9/26778?source=related_link\">",
"      Management of the short bowel syndrome in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/40/35464?source=related_link\">",
"      Obstetrical management of gastroschisis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/15/41205?source=related_link\">",
"      Overview of the development of the gastrointestinal tract",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/3/39992?source=related_link\">",
"      Pathogenesis and etiology of unconjugated hyperbilirubinemia in the newborn",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_55_31609="2D and M mode parasternal short axis echo normal aortic root";
var content_f30_55_31609=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F58902%7ECARD%2F56155%7ECARD%2F79751&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F58902%7ECARD%2F56155%7ECARD%2F79751&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 492px\">",
"   <div class=\"ttl\">",
"    2D and M mode echocardiographic images of the normal aortic root from the parasternal short axis position",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 472px; height: 192px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The M-mode beam is directed through the two dimensional image of the aortic root at the base of the heart (panel A). The resulting M-mode echocardiogram (panel B) demonstrates normal systolic and diastolic motion patterns; the anterior excursion is over 14 mm and the diastolic posterior excursion mainly occurs early in diastole. The aortic (Ao) valve leaflets open as widely as the internal dimensions of the root permit and remain open throughout systole, creating a box-like configuration. The anterior motion of the root and the behavior of the valve are typical findings when the stroke volume is normal.",
"    <div class=\"footnotes\">",
"     PA: main pulmonary artery; LA: left atrium; RVOT: right ventricular outflow tract.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    M-mode echocardiogram of normal aorta and left atrium",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 326px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The M-mode echocardiogram is obtained from the long axis parasternal two dimensional view (panel A); the dotted line represents the M-mode beam passing through the aortic root, the right (R) and noncoronary (N) cusps of the aortic valve, and the left atrium (LA). The atrium is measured at end systole (arrows) when the descent of the left ventricle base has resulted in maximal filling.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 561px\">",
"   <div class=\"ttl\">",
"    Two-dimensional transthoracic echocardiogram (2D TTE) and M mode echocardiographic images along with a phonocardiogram of the normal aortic root from the parasternal short axis position",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 541px; height: 225px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Panel A shows the short axis view from a two-dimensional echocardiogram recorded at the base of the heart at the level of the aortic valve; the line (M) bisecting the aortic valve represents the plane of the M-mode beam used to generate the M-mode echocardiogram in panel B. The aortic valve opens nearly to the aortic (Ao) walls (panel B) and while opened it has a box-like configuration. The line marks the peak of the R wave on the ECG. There is a brisk anterior systolic motion of the entire Ao root and even faster earlier diastolic relaxation (posterior motion); the posterior movement of the aortic root occurs predominantly in early diastole with very little movement in late diastole. This pattern occurs in young healthy hearts that rely predominantly on early relaxation for filling rather than atrial contraction. The M-mode echocardiogram with simultaneous phonocardiogram is seen in panel C. The vibrations on the posterior moving non-coronary aortic leaflet (down arrows) are similar in timing and frequency with the low intensity, early systolic \"innocent\" murmur recorded on the phonocardiogram (up arrows). These vibrations are common in normal valves with normal or elevated cardiac output.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_55_31609=[""].join("\n");
var outline_f30_55_31609=null;
var title_f30_55_31610="Antenatal corticosteroid therapy for reduction of neonatal morbidity and mortality from preterm delivery";
var content_f30_55_31610=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Antenatal corticosteroid therapy for reduction of neonatal morbidity and mortality from preterm delivery",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/55/31610/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/55/31610/contributors\">",
"     Men-Jean Lee, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/55/31610/contributors\">",
"     Debra Guinn, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/55/31610/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/55/31610/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/55/31610/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/55/31610/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/55/31610/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 15, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a landmark paper, Liggins and Howie demonstrated that a single course of antenatal corticosteroid therapy administered to women at risk for preterm delivery (PTD) reduced the incidence and severity of respiratory distress syndrome (RDS) and mortality in offspring [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31610/abstract/1\">",
"     1",
"    </a>",
"    ]. Over a dozen randomized trials have subsequently confirmed these findings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31610/abstract/2\">",
"     2",
"    </a>",
"    ]. In addition, antenatal corticosteroid therapy improves circulatory stability in preterm neonates, resulting in less intraventricular hemorrhage (IVH) or necrotizing enterocolitis compared with unexposed preterm neonates.",
"   </p>",
"   <p>",
"    The National Institutes of Health (NIH) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31610/abstract/3\">",
"     3",
"    </a>",
"    ], the American College of Obstetricians and Gynecologists (ACOG) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31610/abstract/4\">",
"     4",
"    </a>",
"    ], the Royal College of Medicine (RCP) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31610/abstract/5\">",
"     5",
"    </a>",
"    ], and other major organizations have recommended antenatal corticosteroid treatment for women at risk for preterm delivery prior to 34 weeks of gestation to reduce the morbidity and mortality associated with preterm birth. The specific recommendations made by the NIH are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef76628 \" href=\"mobipreview.htm?5/62/6124\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    This topic will review the evidence supporting the use of antenatal corticosteroids to improve neonatal outcomes in women at risk for preterm delivery, pharmacological issues associated with this therapy, and other clinical concerns from administration of antenatal corticosteroids.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MECHANISM OF ACTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antenatal corticosteroid therapy leads to architectural and biochemical changes that improve both lung mechanics (maximal lung volume, compliance) and gas exchange. These changes are primarily the result of accelerated morphologic development of type 1 and type 2 pneumocytes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31610/abstract/6-10\">",
"     6-10",
"    </a>",
"    ]. Type 1 pneumocytes are responsible for gas exchange in the alveoli, while type 2 pneumocytes are responsible for production and secretion of surfactant (",
"    <a class=\"graphic graphic_figure graphicRef64648 \" href=\"mobipreview.htm?39/31/40446\">",
"     figure 1",
"    </a>",
"    ). Antenatal corticosteroids also alter production of surfactant binding proteins and enhance fetal lung antioxidant enzymes. For these changes to occur, however, the lungs need to have reached a stage of development that is biologically responsive to corticosteroids (see",
"    <a class=\"local\" href=\"#H13\">",
"     'Gestational age at administration'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    The biologic rationale for repeating antenatal corticosteroid therapy is based upon the observation that biochemical stimulation of surfactant production appears to be reversible in cell culture models (eg, surfactant protein mRNA levels decline to control levels after cortisol is removed) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31610/abstract/7,11\">",
"     7,11",
"    </a>",
"    ]. However, other beneficial effects, such as cytostructural maturation, persist (in rhesus monkeys) after steroid exposure is withdrawn [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31610/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EVIDENCE OF SHORT-TERM CLINICAL EFFICACY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Reduction of RDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the original study by Liggins and Howie, 282 gravida at high risk for preterm delivery before 37 weeks of gestation were randomly assigned to receive",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/5/44120?source=see_link\">",
"     betamethasone",
"    </a>",
"    (two doses of 12 mg given intramuscularly 24 hours apart) or placebo (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/16/39174?source=see_link\">",
"     cortisone acetate",
"    </a>",
"    6 mg) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31610/abstract/1\">",
"     1",
"    </a>",
"    ]. Administration of betamethasone resulted in a lower incidence of respiratory distress syndrome (RDS) (9.0 versus 25.8 percent in controls) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31610/abstract/1\">",
"     1",
"    </a>",
"    ]. The maximum benefit occurred in the subgroup of infants delivered more than 48 hours but less than seven days after maternal treatment (incidence of RDS: 3.6 versus 33.3 percent in controls), and when the drug was given between 26 and 32 weeks of gestation (incidence of RDS: 11.8 versus 69.6 percent in controls).",
"   </p>",
"   <p>",
"    Subsequent trials performed worldwide have consistently confirmed a significant reduction in the incidence of RDS among infants who received antenatal corticosteroid therapy. In a systematic review of randomized trials comparing antenatal corticosteroid therapy versus",
"    <span class=\"nowrap\">",
"     placebo/no",
"    </span>",
"    treatment, antenatal corticosteroid therapy resulted in a [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31610/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Reduction in RDS (RR 0.66, 95% CI 0.59-0.73, 21 studies, 4038 infants)",
"     </li>",
"     <li>",
"      Reduction in moderate to severe RDS (RR 0.55, 95% CI 0.43-0.71, 6 studies, 1686 infants)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A statistically significant benefit was observed among infants born between one and seven days after the first treatment dose (RR 0.46; 95% CI 0.35-0.60, 9 trials, 1110 infants), but not for those born less than 24 hours or more than seven days after the first dose. The benefits of corticosteroids did not appear to be affected by fetal gender or race [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31610/abstract/13\">",
"     13",
"    </a>",
"    ]. However, these conclusions were based on analysis of subgroups defined after randomization and intervention, which may have biased the results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31610/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Reduction of IVH, NEC, NNM, infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other benefits of antenatal corticosteroid therapy demonstrated by systematic review of randomized trials include reductions in the risk of [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31610/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intraventricular hemorrhage (IVH) (RR 0.54, 95% CI 0.43-0.69; 13 studies, 2872 infants)",
"     </li>",
"     <li>",
"      Necrotizing enterocolitis (NEC) (RR 0.46, 95% CI 0.29-0.74; 8 studies, 1675 infants)",
"     </li>",
"     <li>",
"      Neonatal mortality (NNM) (RR 0.69, 95% CI 0.58-0.81; 18 studies, 3956 infants)",
"     </li>",
"     <li>",
"      Systemic infection in the first 48 hours of life (RR 0.56, 95% CI 0.38-0.85; 5 studies, 1319 infants)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some of these benefits derive from the beneficial effect on respiratory morbidity; however, maturational effects in numerous tissues due to corticosteroid stimulation of developmentally regulated genes and physiological function suggest an independent effect, as well [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31610/abstract/3,15\">",
"     3,15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DRUG AND INITIAL DOSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two regimens of antenatal corticosteroid treatment have evolved; both are effective for accelerating fetal lung maturity. Each regimen is considered a single course of therapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/5/44120?source=see_link\">",
"       Betamethasone",
"      </a>",
"      two doses of 12 mg given intramuscularly 24 hours apart",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       Dexamethasone",
"      </a>",
"      four doses of 6 mg given intramuscularly 12 hours apart",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These steroids are preferred because they are less extensively metabolized by the placental enzyme 11&nbsp;beta-hydroxysteroid dehydrogenase type 2 than other steroids. At these doses, it is estimated that 75 to 80 percent of available corticosteroid receptors are occupied, which should provide near-maximal induction of corticosteroid receptor-mediated response in fetal target tissues [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31610/abstract/16\">",
"     16",
"    </a>",
"    ]. These doses result in cord blood glucocorticoid levels in the range seen with physiologic stress in the preterm neonate.",
"   </p>",
"   <p>",
"    Although data are limited, there is no clear evidence that the beneficial fetal effects of standard doses of antenatal corticosteroids are significantly reduced in overweight women (body mass index [BMI] &ge;25",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"     ),",
"    </span>",
"    but further study of this issue is needed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31610/abstract/17\">",
"     17",
"    </a>",
"    ]. In a randomized trial, maternal and cord blood",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/5/44120?source=see_link\">",
"     betamethasone",
"    </a>",
"    levels were similar for obese (BMI &ge;30",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    and non-obese women; however, this trial did not evaluate clinical outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31610/abstract/18\">",
"     18",
"    </a>",
"    ]. Non-human primate studies are underway to determine if lower, weight-based dosing regimens are as efficacious for lung maturation, while minimizing undesirable side effects.",
"   </p>",
"   <p>",
"    Alternative dosing regimens are unproven, and discussed below. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Alternative dosing regimens'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Betamethasone",
"    </span>",
"    &nbsp;&mdash;&nbsp;One milliliter of the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/5/44120?source=see_link\">",
"     betamethasone",
"    </a>",
"    suspension used in clinical practice (Celestone Soluspan) is actually a combination of 3 mg of betamethasone",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/22/5480?source=see_link\">",
"     sodium phosphate",
"    </a>",
"    and 3 mg of betamethasone acetate. Betamethasone sodium phosphate is soluble so it is rapidly absorbed, while betamethasone acetate is only slightly soluble and, therefore, provides sustained activity. It is only available for intramuscular injection.",
"   </p>",
"   <p>",
"    The biological half-life is 35 to 54 hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31610/abstract/3\">",
"     3",
"    </a>",
"    ]. The onset and duration of action is affected by the vascularity at the injection site. Drug concentrations in cord blood are approximately 20 percent of maternal levels one hour following maternal injection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31610/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Dexamethasone",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     Dexamethasone",
"    </a>",
"    is available as dexamethasone",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/22/5480?source=see_link\">",
"     sodium phosphate",
"    </a>",
"    , which has a rapid onset and relatively short duration of action. Therefore, the dosing frequency of dexamethasone is shorter than that of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/5/44120?source=see_link\">",
"     betamethasone",
"    </a>",
"    . Although dexamethasone is well absorbed from the gastrointestinal tract, evidence of safety and efficacy for fetal maturation has not been established. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Oral administration of dexamethasone'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Comparative studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/5/44120?source=see_link\">",
"     betamethasone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    have mostly been studied in comparison with various controls, rather than in trials comparing the two drugs to each other [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31610/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. This indirect evidence suggested that betamethasone was associated with a greater reduction in the risk of adverse outcome than dexamethasone (",
"    <a class=\"graphic graphic_table graphicRef67486 graphicRef80060 \" href=\"mobipreview.htm?21/4/21580\">",
"     table 2A-B",
"    </a>",
"    ); in particular, betamethasone was associated with a greater reduction in risk of neonatal death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31610/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The only randomized trial directly comparing the two drugs (Betacode trial) found no significant differences between the drugs in the rate of respiratory distress syndrome (RDS), need for vasopressor therapy, necrotizing enterocolitis (NEC), retinopathy of prematurity, patent ductus arteriosus, neonatal sepsis, or neonatal mortality (NNM) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31610/abstract/21\">",
"     21",
"    </a>",
"    ]. However, neonates exposed to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/5/44120?source=see_link\">",
"     betamethasone",
"    </a>",
"    had a significantly higher rate of intraventricular hemorrhage (IVH) (17 percent",
"    <span class=\"nowrap\">",
"     [17/100]",
"    </span>",
"    versus 6 percent",
"    <span class=\"nowrap\">",
"     [6/105],",
"    </span>",
"    RR 2.97, 95% CI 1.22-7.24) and brain lesions (18 percent",
"    <span class=\"nowrap\">",
"     [18/100]",
"    </span>",
"    versus 7 percent",
"    <span class=\"nowrap\">",
"     [7/105],",
"    </span>",
"    RR 2.7, 95%CI 1.18-6.19). Long-term outcome data were not available. The small number of subjects and adverse outcomes in this trial warrants caution in interpretation of these findings.",
"   </p>",
"   <p>",
"    These findings are in conflict with several larger cohort and case control studies that suggested antenatal use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    was neurotoxic and associated with a greater risk of adverse neurologic outcomes compared to use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/5/44120?source=see_link\">",
"     betamethasone",
"    </a>",
"    or no steroid treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31610/abstract/20,22-28\">",
"     20,22-28",
"    </a>",
"    ]. Studies of postnatal use of dexamethasone for lung disease of prematurity have also associated its use with shorter stature, smaller head circumference, poorer motor skills and coordination, lower IQ scores, and an increased frequency of clinically significant disabilities in school-aged survivors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31610/abstract/29\">",
"     29",
"    </a>",
"    ]. Other studies have not observed adverse effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31610/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Investigators have hypothesized that adverse effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    on the developing brain may be gestational age dependent or related to the length of the exposure (prenatal and postnatal). Alternatively, the presence of sulfating agents in commonly available dexamethasone preparations may be neurotoxic, thereby mitigating the potential benefits of the corticosteroid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31610/abstract/31,32\">",
"     31,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In summary, studies have consistently found that both",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/5/44120?source=see_link\">",
"     betamethasone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    are effective in reducing most prematurity-related morbidity and mortality. Dexamethasone has the advantage of lower cost and wider availability, but relatively increased risk of neurotoxicity is a concern. Currently, there is insufficient high-quality evidence on possible adverse effects on which to base a strong recommendation for use of one drug over the other [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31610/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22617742\">",
"    <span class=\"h2\">",
"     Hydrocortisone",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/49/32528?source=see_link\">",
"     Hydrocortisone",
"    </a>",
"    is extensively metabolized by placental enzymes so relatively little crosses into the fetal compartment; therefore, beneficial fetal effects may not occur. However, if both",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/5/44120?source=see_link\">",
"     betamethasone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    are unavailable due to drug shortages, hydrocortisone 500 mg intravenously every 12 hours for four doses has been proposed as a last resort [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31610/abstract/34,35\">",
"     34,35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In women incidentally receiving high dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    for treatment of a medical disorder, a standard course of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/5/44120?source=see_link\">",
"     betamethasone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    , when indicated for fetal lung maturation, is still recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     GESTATIONAL AGE AT ADMINISTRATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend administration of antenatal corticosteroids to pregnant woman at 23 to 34 weeks who are at increased risk of preterm delivery within the next seven days.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2337777\">",
"    <span class=\"h2\">",
"     23 to 34 weeks",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 2006 meta-analysis of randomized trials of antenatal corticosteroids in women at risk of preterm birth provided strong evidence that respiratory distress syndrome (RDS), intraventricular hemorrhage (IVH), and neonatal death are significantly reduced when corticosteroids are given at 26 to 34 weeks of gestation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31610/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The benefit of administering antenatal corticosteroids before 26 weeks of gestation was suggested by a 2011 prospective cohort study including over 10,000 infants born at 22 to 25 weeks of gestation at 23 academic perinatal centers in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31610/abstract/36\">",
"     36",
"    </a>",
"    ]. Compared to no exposure to antenatal steroids, the composite outcome &lsquo;death or neurodevelopmental impairment at 18 to 22 months of age&rsquo; was significantly lower for steroid exposed fetuses (adjusted odds ratio [AOR] 0.60, 95% CI 0.53-0.69). The benefit of antenatal steroids was significant for infants born at:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      23 weeks of gestation (83.4 versus 90.5 percent; AOR 0.58, 95% CI 0.42-0.80)",
"     </li>",
"     <li>",
"      24 weeks of gestation (68.4 versus 80.3 percent; AOR 0.62, 95% CI 0.49-0.78)",
"     </li>",
"     <li>",
"      25 weeks of gestation (52.7 versus 67.9 percent; AOR 0.61, 95% CI 0.50-0.74)",
"     </li>",
"     <li>",
"      but",
"      <strong>",
"       not",
"      </strong>",
"      at 22 weeks of gestation (90.2 versus 93.1; AOR 0.80, 95% CI 0.29-2.21)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Corticosteroid exposed infants born at 23, 24, and 25 weeks of gestation also had significant reductions in the following outcomes: death by 18 to 22 months; hospital death; death, intraventricular hemorrhage, or periventricular leukomalacia; and death or necrotizing enterocolitis.",
"   </p>",
"   <p>",
"    It is unlikely that administration of antenatal corticosteroids at &le;22 weeks of gestation would significantly improve lung function, as there are only a few primitive alveoli at this gestational age on which the drug can exert an effect (see",
"    <a class=\"local\" href=\"#H2\">",
"     'Mechanism of action'",
"    </a>",
"    above) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31610/abstract/37\">",
"     37",
"    </a>",
"    ]. However, if well-counseled parents elect to pursue active resuscitation of neonates &le;22 weeks despite high rates of long-term handicap, then it is reasonable to administer a course of antenatal corticosteroids prior to delivery. Parents should be informed that this intervention may provide a survival benefit while increasing the risk of survival with severe impairment. Also, if the pregnancy is not delivered, then \"salvage\" or repeat courses of antenatal corticosteroids may need to be considered later in gestation (see",
"    <a class=\"local\" href=\"#H667637\">",
"     'Use of repeated courses of therapy'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2337770\">",
"    <span class=\"h2\">",
"     After 34 weeks",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether there is a significant improvement in outcome following antenatal corticosteroid use after 34 weeks of gestation is unclear since the baseline risks of RDS, IVH, and neonatal mortality are already low at that time. Given the lack of high-quality data in this population, the National Institutes of Health (NIH) Consensus Development Conference on the Effect of Glucocorticoids for Fetal Maturation on Perinatal Outcomes stated that administration of antenatal corticosteroids after 34 weeks can be considered if there is evidence of pulmonary immaturity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31610/abstract/3\">",
"     3",
"    </a>",
"    ]. This position has been supported by a subsequently published trial. In the ASTECS (Antenatal Steroids for Term Caesarean Section) trial, 998 women were randomly assigned to receive a course of antenatal corticosteroids or no antenatal corticosteroids 48 hours before planned cesarean delivery at &ge;37 weeks of gestation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31610/abstract/38\">",
"     38",
"    </a>",
"    ]. The overall incidence of respiratory problems (composite of transient tachypnea of the newborn [TTN] and RDS) was lower in neonates who were treated antenatally (2.4 versus 5.1 percent; RR 0.46, 95% CI 0.23-0.93). In addition, another randomized trial provided indirect evidence of efficacy. In this trial, administration of antenatal corticosteroids at 34 to 37 weeks in pregnancies with documented fetal lung immaturity significantly increased the level of at least one test of fetal lung maturity (increase in TDx- FLM-II: 28.4 versus 9.8 without treatment) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31610/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On the other hand, a Brazilian placebo-controlled randomized trial found no benefit from administration of a course of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/5/44120?source=see_link\">",
"     betamethasone",
"    </a>",
"    to women at 34 to 36 weeks of gestation at risk of imminent premature delivery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31610/abstract/40\">",
"     40",
"    </a>",
"    ]. The rate of RDS was low",
"    <span class=\"nowrap\">",
"     (2/143",
"    </span>",
"    in the corticosteroid group and",
"    <span class=\"nowrap\">",
"     1/130",
"    </span>",
"    in the placebo group), while the rate of TTN was similar and high in both groups",
"    <span class=\"nowrap\">",
"     (34/143",
"    </span>",
"    [24 percent] versus",
"    <span class=\"nowrap\">",
"     29/130",
"    </span>",
"    [22 percent]). The study was not powered to detect differences in the rate of RDS. There was also no reduction in the risk of composite respiratory morbidity with corticosteroid use: adjusted risk of respiratory morbidity 1.12 (95% CI 0.74-1.70;",
"    <span class=\"nowrap\">",
"     36/143",
"    </span>",
"    [25 percent] versus",
"    <span class=\"nowrap\">",
"     30/130",
"    </span>",
"    [23 percent]), even after adjustment for subgroups by week of gestation (34",
"    <sup>",
"     th",
"    </sup>",
"    , 35",
"    <sup>",
"     th",
"    </sup>",
"    , 36",
"    <sup>",
"     th",
"    </sup>",
"    ). There was no significant difference between groups in neonatal morbidity",
"    <span class=\"nowrap\">",
"     (88/143",
"    </span>",
"    [62 percent] versus",
"    <span class=\"nowrap\">",
"     93/130",
"    </span>",
"    [72 percent]) or in the duration of hospital stay (5.12 versus 5.22 days). Phototherapy for jaundice was required less often in babies whose mothers received corticosteroids (RR 0.63, 95% CI 0.44-0.91).",
"   </p>",
"   <p>",
"    There are limited long-term follow-up data on neurologic outcomes in children exposed to antenatal steroids after 34 weeks of gestation. In both humans and animal models, the impact of antenatal steroids on brain development depends on the gestational age at exposure. Early in gestation, antenatal steroid exposure may delay myelination; however, near term, as the brain becomes much more mitotically active, steroid exposure results in cell death, which has a more serious impact on brain growth and function. However, a study of responses to a questionnaire sent to participants of the ASTECS trial (described above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31610/abstract/38\">",
"     38",
"    </a>",
"    ]) 8 to 15 years after delivery reported antenatal",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/5/44120?source=see_link\">",
"     betamethasone",
"    </a>",
"    administered at 37 to 38 weeks of gestation did not appear to result in any adverse outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31610/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because of the low risk of severe respiratory morbidity after 34 weeks of gestation, the lack of consistent evidence of corticosteroid efficacy, and the theoretic potential for long-term harm following late exposure, we suggest avoiding use of antenatal corticosteroids after 34 weeks of gestation. The American College of Obstetricians and Gynecologists (ACOG) has not recommended antenatal corticosteroids for gestations &gt;34 weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31610/abstract/4,42\">",
"     4,42",
"    </a>",
"    ]. However, the Royal College of Obstetrics and Gynaecology (RCOG) guidelines recommend routine administration of antenatal glucocorticoids for all women undergoing elective cesarean delivery before 39 weeks of gestation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31610/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     TIMING BEFORE DELIVERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antenatal corticosteroid therapy should be administered to all women at high risk for preterm delivery unless \"impending\" delivery (eg, birth expected within an hour or two) is anticipated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31610/abstract/3\">",
"     3",
"    </a>",
"    ]. Therapy should not be withheld if delivery is anticipated prior to the completion of the full dose of medication. This liberal approach to treatment is recommended because the minimal time interval between drug administration and delivery required to achieve neonatal benefits has not been clearly defined and the hour of delivery cannot be predicted accurately.",
"   </p>",
"   <p>",
"    Several observations suggest neonatal benefits begin to accrue within a few hours of corticosteroid administration. Cell cultures have shown that choline begins to be incorporated into phospholipids at 6 hours and peaks at 48 hours post-injection of antenatal corticosteroids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31610/abstract/44\">",
"     44",
"    </a>",
"    ]. Decreased lung albumin is detectable as early as eight hours following antenatal corticosteroid exposure in the fetal lamb model [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31610/abstract/45\">",
"     45",
"    </a>",
"    ]. By 15 hours following antenatal corticosteroid administration, decreases in both lung albumin and ventilatory pressure and increases in maximum lung volume are observed. In addition, infants who received one dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/5/44120?source=see_link\">",
"     betamethasone",
"    </a>",
"    in utero, but delivered before the second dose could be given, had better outcomes than infants who did not receive any antenatal corticosteroids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31610/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SAFETY AND SIDE EFFECTS OF A SINGLE COURSE THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Administration of a single course of antenatal corticosteroid therapy (ie, two doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/5/44120?source=see_link\">",
"     betamethasone",
"    </a>",
"    or four doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    ) appears to be safe for the",
"    <span class=\"nowrap\">",
"     fetus/infant",
"    </span>",
"    and mother, but has some side effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Potential fetal side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Administration of antenatal corticosteroids may be associated with transient fetal heart rate (FHR) and behavioral changes that typically return to baseline by four to seven days after treatment. The most consistent FHR finding is a decrease in FHR variability on days two and three after administration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31610/abstract/47-51\">",
"     47-51",
"    </a>",
"    ]. Reduced fetal breathing and body movements have also been described, resulting in a lower biophysical profile (BPP) score or nonreactive nonstress test (NR-NST) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31610/abstract/51-54\">",
"     51-54",
"    </a>",
"    ]. However, this is not a consistent finding; a placebo-controlled randomized trial in humans did not report a decrease in maternal perception of fetal movements in patients who received antenatal corticosteroids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31610/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    FHR and behavioral changes may reflect a direct physiologic response of the brain to corticosteroids or they may be an indirect result of a transient increase in fetal vascular resistance and blood pressure, which has been demonstrated in some animal studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31610/abstract/55-59\">",
"     55-59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Three human studies have demonstrated a transient improvement in umbilical artery end-diastolic flow in 63 to 71 percent of their study populations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31610/abstract/60-62\">",
"     60-62",
"    </a>",
"    ]. The improvement began about eight hours after the first dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/5/44120?source=see_link\">",
"     betamethasone",
"    </a>",
"    and lasted a median of three days (range 1 to 10 days). However, other studies have not observed effects on fetal blood flow velocity waveform patterns in the umbilical artery, middle cerebral artery, or ductus venosus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31610/abstract/53,63\">",
"     53,63",
"    </a>",
"    ]. Preterm fetuses with severe early-onset growth restriction and absent or reversed end-diastolic umbilical artery flow (EDF) do not have a consistent cardiovascular response to maternal betamethasone administration. Some exhibit transient improvement of EDF, while others do not. The latter group appears to be at higher risk of severe intrauterine acidosis or death. However, these observations are based on a small number of events in two studies and need to be confirmed before a change in management of this subgroup of fetuses is considered [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31610/abstract/62,64\">",
"     62,64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When assessing a fetus for possible delivery because of a nonreassuring fetal evaluation (eg, NR-NST or low BPP score) within two or three days of corticosteroid administration, the possibility of transient mild changes in test results related to antenatal corticosteroid administration is a factor that should be considered. Whether continued close fetal monitoring or delivery is indicated in this setting depends on assessment of the total clinical scenario and clinical judgment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1498435\">",
"    <span class=\"h2\">",
"     Potential long-term side effects",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22617614\">",
"    <span class=\"h3\">",
"     Infants",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 2006 systematic review of data from randomized trials found that a single course of antenatal corticosteroids did not increase the risk of any adverse infant outcome, including neonatal sepsis, small for gestational age infant, hypothalamic-pituitary-adrenal (HPA) suppression, or air leak syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31610/abstract/2\">",
"     2",
"    </a>",
"    ]. However, further research is needed, as several studies of infants exposed to antenatal corticosteroids have observed reduced basal and stress-induced cortisol secretion in these infants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31610/abstract/65-68\">",
"     65-68",
"    </a>",
"    ]; this subject has been reviewed in detail elsewhere [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31610/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Children and adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;Follow-up studies at ages 3 to 6, 12, 22, and 30 years have not reported adverse effects on growth, lung function, and psychosexual, motor, cognitive, neurologic, and ophthalmologic outcomes in antenatal corticosteroid exposed",
"    <span class=\"nowrap\">",
"     children/adults",
"    </span>",
"    compared with unexposed controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31610/abstract/6,70-75\">",
"     6,70-75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, other potentially adverse effects have been reported and require further study. For example:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A cross-sectional study of 209 term-born children at 6 to 11 years of age observed significantly increased cortisol reactivity to acute psychosocial stress in those exposed to antenatal synthetic corticosteroid treatment compared to controls [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/55/31610/abstract/76\">",
"       76",
"      </a>",
"      ]. It has been hypothesized that antenatal corticosteroids lead to prenatal programming of a hyperactive HPA-axis, which may increase these children&rsquo;s risk for cardiovascular and affective disorders later in life.",
"     </li>",
"     <li>",
"      In the Auckland Steroid Trial, which is the largest and longest follow-up study of individuals exposed to antenatal corticosteroids, 253 adults from",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/5/44120?source=see_link\">",
"       betamethasone",
"      </a>",
"      treated pregnancies and 281 adults from placebo-treated control pregnancies were evaluated at a mean age of 30 years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/55/31610/abstract/74\">",
"       74",
"      </a>",
"      ]. Antenatal corticosteroid-exposed adults displayed small, although statistically significant, increases in insulin resistance, but no difference in cardiovascular risk factors compared to unexposed controls. There were no differences between groups in cognitive functioning, working memory and attention, psychiatric morbidity, handedness, or health related quality of life [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/55/31610/abstract/75\">",
"       75",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another long-term outcome study in a British cohort of young adults reported antenatal corticosteroid exposure was associated with increased aortic arch stiffness and altered glucose metabolism in adulthood [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/55/31610/abstract/77\">",
"       77",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Maternal side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most pregnant women tolerate a single course of antenatal corticosteroids without difficulty. In a systematic review of randomized trials, treatment did not increase the risk of maternal death, chorioamnionitis, or puerperal sepsis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31610/abstract/2\">",
"     2",
"    </a>",
"    ]. Case reports have described pulmonary edema, primarily associated with combination treatment with tocolytics, especially in the setting of chorioamnionitis, fluid overload, or multiple gestation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31610/abstract/78-80\">",
"     78-80",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/5/44120?source=see_link\">",
"     Betamethasone",
"    </a>",
"    itself has low mineralocorticoid activity compared to other corticosteroids; therefore, hypertension is not a contraindication to therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31610/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Transient hyperglycemia occurs in many women; the steroid effect begins approximately 12 hours after the first dose and may last for five days. Screening for gestational diabetes, if indicated, should be performed either before corticosteroid administration or at least five days after the first dose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31610/abstract/82,83\">",
"     82,83",
"    </a>",
"    ]. Hyperglycemia can be severe in the diabetic gravida if not closely monitored and treated. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/62/35818?source=see_link&amp;anchor=H20#H20\">",
"     \"Obstetrical management of pregnancy complicated by pregestational diabetes mellitus\", section on 'Antenatal glucocorticoids'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The total leukocyte count increases by about 30 percent within 24 hours after",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/5/44120?source=see_link\">",
"     betamethasone",
"    </a>",
"    injection, and the lymphocyte count significantly decreases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31610/abstract/84,85\">",
"     84,85",
"    </a>",
"    ]. These changes return to baseline values within three days, and complicate interpretation of the white blood cell count in women suspected of infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H667637\">",
"    <span class=\"h1\">",
"     USE OF REPEATED COURSES OF THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;When more than seven days elapse between the initial course of steroid therapy and preterm delivery, administering a repeat course of therapy reduces the risk of respiratory distress syndrome (RDS). Evidence for repeating steroid therapy was provided by a 2011 systematic review of randomized trials that assessed the effectiveness and safety of repeated doses of antenatal",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/5/44120?source=see_link\">",
"     betamethasone",
"    </a>",
"    versus no repeat courses for women who remain at risk of preterm birth &ge;7 days after an initial course of therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31610/abstract/86\">",
"     86",
"    </a>",
"    ]. Compared to a single course of therapy, repeated courses of betamethasone resulted in:",
"   </p>",
"   <p>",
"    For the neonate",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Reduced risk of RDS (RR 0.83, 95% CI 0.75-0.91, 8 trials, 3206 infants, numbers needed to treat [NNT] 17, 95% CI 11-32)",
"     </li>",
"     <li>",
"      Reduced risk of composite serious infant outcomes (RR 0.84, 95% CI 0.75-0.94, 7 trials, 5094 infants, NNT 30, 95% CI 19-79). Serious infant outcomes were variably defined in each trial and included perinatal death, bronchopulmonary dysplasia, severe intraventricular hemorrhage, necrotizing enterocolitis, sepsis, periventricular leukomalacia,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      retinopathy of prematurity.",
"      <br/>",
"      <br/>",
"      However, repeated dosing did not result in statistically significant reductions in risk for individual outcomes of severe lung disease (RR 0.80, 95% CI 0.56-1.14, 6 trials, 4826), perinatal mortality (RR 0.94, 95% CI 0.71-1.23, 9 trials, 5554 infants), chronic lung disease (RR 1.06, 95% CI 0.87-1.30, 8 trials, 5393 infants), or intraventricular hemorrhage (RR 0.94, 95% CI 0.75-1.18, 6 trials, 3065 infants).",
"     </li>",
"     <li>",
"      Reduction in mean birthweight (mean difference -75.79 g, 95% CI -117.63 to -33.96, 9 trials, 5626 infants), which was not statistically significant when birthweight was adjusted for gestational age.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For the mother",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      No significant increase in chorioamnionitis (RR 1.16, 95% CI 0.92-1.46, 6 trials, 4261 women)",
"     </li>",
"     <li>",
"      No significant increase in puerperal sepsis (RR 1.15, 95% CI 0.83-1.60, 5 trials, 3091 women)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For the young child",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      No significant harm or benefit. At follow-up in early childhood (18 months to 2 years corrected age), there were no statistically significant differences in total deaths; survival free of any disability or major disability; major disability; composite serious outcome; growth assessment (weight, height); developmental delay; blindness; deafness; or cerebral palsy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, we and others [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31610/abstract/69\">",
"     69",
"    </a>",
"    ] remain concerned about administering multiple repeat courses of steroid therapy because the systematic review did not evaluate whether there was an increased risk of harm as the number of repeat courses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/5/44120?source=see_link\">",
"     betamethasone",
"    </a>",
"    increased. Individual trials suggest increasing exposure to steroids is associated with increasing risk of adverse effect:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the Maternal Fetal Medicine Units network (MFMU) trial, 63 percent of patients received 4 or more courses of therapy. This trial found that the percentage of small for gestational age (SGA) fetuses below the 10th percentile and below the 5th percentile was significantly higher in the repeated steroid course group compared to the single course group (for the 10th percentile: 19.3 versus 8.4 percent; for the 5th percentile 10.4 versus 4.7 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/55/31610/abstract/87\">",
"       87",
"      </a>",
"      ]. After 32 weeks of gestation, placental weight was significantly less in the repeat corticosteroid group, and was related inversely to the number of steroid courses [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/55/31610/abstract/88\">",
"       88",
"      </a>",
"      ]. Although statistically nonsignificant, repeat courses were associated with an increased incidence of cerebral palsy (one case of cerebral palsy in the control group and five in the weekly steroid group; RR 5.68, 95% CI 0.69-46.7); five of the six children with cerebral palsy were delivered near term or term and five of the six were exposed to &ge;4 courses of antenatal corticosteroids [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/55/31610/abstract/87\">",
"       87",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A secondary analysis of data from the Multiple Courses of Antenatal Corticosteroids for Preterm Birth Study, a randomized trial of single versus multiple course steroid therapy, reported a dose-response relationship between the number of corticosteroid courses and a decrease in fetal growth [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/55/31610/abstract/89\">",
"       89",
"      </a>",
"      ]. Multiple courses of therapy were not associated with an increased risk of maternal side effects [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/55/31610/abstract/90\">",
"       90",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although fetal growth may be impaired by repeated courses of antenatal corticosteroids, there is some evidence that catch-up growth occurs after delivery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31610/abstract/91\">",
"     91",
"    </a>",
"    ]. More longitudinal follow-up studies need to be performed to determine the long-term effects of multiple courses of antenatal corticosteroid therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6150007\">",
"    <span class=\"h2\">",
"     Salvage (rescue) therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Salvage (rescue) therapy is an attractive alternative to routinely repeating weekly courses of antenatal corticosteroids once an initial course has been given. Salvage therapy is limited to pregnancies estimated to be at high risk of delivering within seven days. In theory, this would allow a single booster or rescue course of therapy to those pregnancies most likely to benefit. This could result in a reduction in RDS without increasing the risk of potentially adverse outcomes.",
"   </p>",
"   <p>",
"    Three placebo-controlled randomized trials of salvage therapy have been published. One trial (n = 249 pregnancies) did not show a reduction in the incidence of RDS with salvage therapy (52 percent with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/5/44120?source=see_link\">",
"     betamethasone",
"    </a>",
"    versus 48 percent with placebo) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31610/abstract/92\">",
"     92",
"    </a>",
"    ], while the other (n = 437 pregnancies) reported a significant reduction in RDS (41.4 percent",
"    <span class=\"nowrap\">",
"     [67/162]",
"    </span>",
"    with betamethasone versus 61.6 percent",
"    <span class=\"nowrap\">",
"     [101/164]",
"    </span>",
"    with placebo; OR 0.45, 95% CI 0.27-0.75) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31610/abstract/93\">",
"     93",
"    </a>",
"    ]. A higher proportion of subjects that actually received the intervention in the second trial compared to the first trial likely accounted for the significant reduction in RDS. A third placebo-controlled randomized trial (n = 85 pregnancies) also suggested a benefit: a rescue course of betamethasone significantly increased respiratory compliance (primary outcome) and, in deliveries less than 34 weeks, significantly decreased the incidence of RDS",
"    <span class=\"nowrap\">",
"     (15/44",
"    </span>",
"    [34 percent] versus",
"    <span class=\"nowrap\">",
"     22/39",
"    </span>",
"    [56 percent] in the placebo group) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31610/abstract/94\">",
"     94",
"    </a>",
"    ]. When deliveries at all gestational ages were included, the reduction in RDS remained but was not statistically significant",
"    <span class=\"nowrap\">",
"     (15/56",
"    </span>",
"    [27 percent] versus",
"    <span class=\"nowrap\">",
"     23/56",
"    </span>",
"    [41 percent]).",
"    <br/>",
"    <br/>",
"    Although none of these trials reported a statistically increased risk of adverse effects (eg, growth restriction), no firm conclusions can be made since the number of subjects and events was small and the infants were followed for only a short time after birth.",
"   </p>",
"   <p>",
"    In 2011 and 2012, the American College of Obstetricians and Gynecologists (ACOG) endorsed&nbsp;the concept of a single course of salvage or rescue steroids in women who remain at risk of preterm delivery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31610/abstract/4,42\">",
"     4,42",
"    </a>",
"    ]. The 2011 and 2012 publications differ with respect to the minimal time interval before providing rescue treatment (at least 7 versus 14 days) and the maximum gestational age (&lt;33 versus &lt;34 weeks). Both publications recommend avoiding regularly scheduled repeat courses or more than two courses of antenatal corticosteroids.",
"   </p>",
"   <p>",
"    The Australasian Collaborative Trial of Repeat Doses of Steroids (ACTORDS) demonstrated that repeat dosing with only a single injection of corticosteroids was as effective as the two injection standard [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31610/abstract/95\">",
"     95",
"    </a>",
"    ]. Therefore, in our practice, we give a single dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/5/44120?source=see_link\">",
"     betamethasone",
"    </a>",
"    as salvage therapy to minimize fetal steroid exposure.",
"   </p>",
"   <p>",
"    We administer a single dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/5/44120?source=see_link\">",
"     betamethasone",
"    </a>",
"    salvage therapy to pregnancies with all of the following characteristics, as we feel the benefit to risk ratio is most favorable in this setting:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clinically estimated to be at high risk of delivery within the next seven days",
"     </li>",
"     <li>",
"      Initial course of antenatal corticosteroids at &lt;28 weeks of gestation",
"     </li>",
"     <li>",
"      Prior exposure to antenatal corticosteroids at least two weeks earlier",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     ALTERNATIVE DOSING REGIMENS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no strong evidence supporting the safety and efficacy of increasing the steroid dose, accelerating the dosing interval, or using an intravenous or oral route of administration. There is moderate evidence to support the use of one additional dose of therapy in pregnancies that completed a single course of therapy at an early gestational age more than a week or two prior to expected delivery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Higher dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pharmacokinetic studies by Ballard and Ballard demonstrated that the standard dosing intervals of two 12 mg doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/5/44120?source=see_link\">",
"     betamethasone",
"    </a>",
"    administered 24 hours apart provide maximum glucocorticoid receptor occupancy and near-maximal stimulation of glucocorticoid receptor target genes in fetal tissues [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31610/abstract/7,96,97\">",
"     7,96,97",
"    </a>",
"    ]. If receptors are not available for activation, then a higher daily dose of glucocorticoid would not be expected to increase efficacy and the excess drug would likely be excreted. In addition, supraphysiological doses of glucocorticoids are known to induce suppression of glucocorticoid receptor levels by a process known as &ldquo;homologous down-regulation&rdquo; [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31610/abstract/98\">",
"     98",
"    </a>",
"    ]. Thus, administration of a higher dose of steroid would probably result in, at most, a negligible increase in fetal lung maturation. This hypothesis was supported by a study in which doubling the dose of betamethasone to 24 mg per day in the clinical setting was not associated with increased efficacy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31610/abstract/99\">",
"     99",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21501907\">",
"    <span class=\"h2\">",
"     Shorter dosing interval",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a non-inferiority trial that evaluated the safety and efficacy of using a shorter dosing interval, the incidence of respiratory distress syndrome (RDS) with a 12-hour dosing interval was not statistically inferior to that with a 24-hour dosing interval (RDS incidence",
"    <span class=\"nowrap\">",
"     61/167",
"    </span>",
"    [36.5 percent] versus",
"    <span class=\"nowrap\">",
"     28/75",
"    </span>",
"    [37.3 percent]) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31610/abstract/100\">",
"     100",
"    </a>",
"    ]. There were no statistically significant differences between groups in any neonatal outcome, except that all 10 cases of necrotizing enterocolitis among the 260 infants in the trial occurred in the accelerated 12-hour dosing group",
"    <span class=\"nowrap\">",
"     (10/161",
"    </span>",
"    [6.2 percent] versus",
"    <span class=\"nowrap\">",
"     0/70,",
"    </span>",
"    P = 0.03). This difference may have been due to chance, given the small number of subjects and events. A retrospective study found similar neonatal outcomes for 12-hour and 24-hour dosing intervals when delivery occurred within 48 hours of initiation of therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31610/abstract/101\">",
"     101",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The possibility of an increased risk of necrotizing enterocolitis with a shorter dosing interval is concerning; therefore, we feel that this practice should be avoided until data from appropriately powered randomized trials demonstrate efficacy and safety.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Intravenous administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical efficacy of intravenous antenatal corticosteroids has not been studied in human pregnancy. Intravenous administration results in rapid peaks and troughs in maternal and fetal steroid concentrations. This produces less sustained fetal exposure to corticosteroid stimulation and thus may not be as effective as intramuscular administration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Oral administration of dexamethasone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Outpatient oral administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    has been used to facilitate completion of full courses of corticosteroids in ambulatory women at increased risk of preterm delivery. In the only randomized trial of this approach, 170 women between 24 and 33 weeks of gestation at high risk of preterm delivery were randomly assigned to receive either 6 mg intramuscular dexamethasone or 8 mg oral dexamethasone every 12 hours for 4 doses, repeated weekly until 34 weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31610/abstract/102\">",
"     102",
"    </a>",
"    ]. There was no statistical difference between groups in the frequency of RDS, but the oral dexamethasone group had significantly higher rates of intraventricular hemorrhage (IVH) and sepsis, leading to premature discontinuation of the trial after 39 percent enrollment. The authors concluded that oral dexamethasone should not be given in place of intramuscular administration. In the absence of adequate data establishing the safety and efficacy of oral therapy for fetal maturation, we recommend using only intramuscular therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     AMNIOCENTESIS AFTER ANTENATAL CORTICOSTEROID THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Standard tests for predicting fetal lung maturity may be less predictive of RDS after antenatal corticosteroids. Although some studies have reported an increased lecithin-sphingomyelin ratio or TDx-FLM II five days to two weeks after corticosteroid therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31610/abstract/39,103,104\">",
"     39,103,104",
"    </a>",
"    ], several other series found no change in this ratio [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31610/abstract/1,105,106\">",
"     1,105,106",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We do",
"    <strong>",
"     not",
"    </strong>",
"    recommend routine amniocentesis following antenatal corticosteroid therapy because current tests for fetal lung maturation may not be sufficiently sensitive to detect subtle changes in the surfactant concentration of amniotic fluid. In addition, these tests cannot assess the effects of architectural changes in the fetal lung. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/58/42919?source=see_link\">",
"     \"Assessment of fetal lung maturity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10508471\">",
"    <span class=\"h1\">",
"     SPECIAL POPULATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Preterm premature rupture of membranes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The peripartum period, especially in the setting of preterm premature rupture of membranes (PPROM), is a high risk period for maternal, fetal, and neonatal infection. There have been concerns that the immunosuppressive properties of corticosteroids may augment this risk. In 1994, the National Institutes of Health (NIH) consensus panel concluded that the benefits of antenatal corticosteroids outweighed the infection risk and, therefore, recommended antenatal corticosteroid therapy for pregnancies complicated by PPROM at less than 30 to 32 weeks of gestation, as long as there was no clinical evidence of chorioamnionitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31610/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Data supporting this recommendation have been provided by two systematic reviews [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31610/abstract/2,107\">",
"     2,107",
"    </a>",
"    ] that showed neonatal death, respiratory distress syndrome (RDS), intraventricular hemorrhage (IVH), necrotizing enterocolitis (NEC), and duration of neonatal respiratory support were significantly reduced by corticosteroid treatment, without an increase in either maternal or neonatal infection. Mean risk reduction for these adverse events ranged from 30 to 60 percent.",
"   </p>",
"   <p>",
"    The effect of single versus weekly courses of antenatal corticosteroids specifically in women with PPROM was evaluated in a planned secondary analysis of participants in the large, randomized trial of single versus repeated courses of antenatal corticosteroid therapy discussed above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31610/abstract/108\">",
"     108",
"    </a>",
"    ]. In pregnancies complicated by PPROM, weekly courses of antenatal corticosteroids did not significantly improve neonatal outcome, except severe RDS (which was reduced from 39 to 19 percent), beyond that achieved with a single treatment course [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31610/abstract/109\">",
"     109",
"    </a>",
"    ]. Weekly courses were associated with shorter latency and increased risks of chorioamnionitis and neonatal sepsis. The decrease in severe RDS with multi-course therapy resulted in less composite neonatal morbidity among neonates delivered at 24 to 27 weeks of gestation (severe RDS was decreased from 100 to 26 percent in this age group); however, the decrease in composite morbidity did not reach statistical significance after adjusting for multiple comparisons. Secondary analysis of this trial also demonstrated that there was no benefit to receiving antenatal corticosteroids between 32 and 34 weeks of gestation, and that exposure at this gestational age increased the likelihood of chorioamnionitis. Moreover, the risk of chorioamnionitis outweighed any risk of complications related to prematurity after 32 weeks of gestation.",
"   </p>",
"   <p>",
"    Given limitations in available data, there are wide practice variations in antenatal corticosteroid treatment of PPROM. Based on the findings discussed above and NIH recommendations, we do not use antenatal corticosteroids beyond 32 weeks of gestation in PPROM. The American College of Obstetricians and Gynecologists (ACOG) has stated treatment at 32 to 33 completed weeks may be beneficial if pulmonary immaturity has been documented, although efficacy has not been proven [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31610/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As discussed above, a single course of &ldquo;rescue&rdquo; therapy can be considered if multiple weeks have elapsed since the initial course of antenatal corticosteroid therapy and the gestational age remains less than 32 weeks. The overall management of PPROM is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/31/15866?source=see_link\">",
"     \"Preterm premature rupture of membranes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10508416\">",
"    <span class=\"h2\">",
"     Multiple gestation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The small number of multiple gestations included in trials precludes a definite conclusion about the effectiveness of this therapy or optimum dose in these pregnancies (multiple gestation RR RDS 0.85, 95% CI 0.60-1.20) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31610/abstract/2\">",
"     2",
"    </a>",
"    ]. In theory, multiple gestations may require higher doses of antenatal corticosteroids to maximize fetal exposure. However, a randomized trial found that maternal and cord blood",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/5/44120?source=see_link\">",
"     betamethasone",
"    </a>",
"    levels were similar in singleton and multiple gestations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31610/abstract/18\">",
"     18",
"    </a>",
"    ]. This trial did not compare clinical outcomes. A prospective pharmacokinetic study also found pharmacokinetics were the same in singleton and multiple gestations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31610/abstract/110\">",
"     110",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We agree with the NIH consensus statement which suggested using the standard dosing schedule for both singleton and multiple gestations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31610/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/46/40682?source=see_link&amp;anchor=H38#H38\">",
"     \"Twin pregnancy: Prenatal issues\", section on 'Antenatal corticosteroids'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18289464\">",
"    <span class=\"h2\">",
"     Hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/5/44120?source=see_link\">",
"     Betamethasone",
"    </a>",
"    has low mineralocorticoid activity compared to other corticosteroids and does not aggravate hypertension. Data from a randomized trial support both the safety and efficacy of antenatal corticosteroid therapy in pregnancies complicated by severe preeclampsia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31610/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18289519\">",
"    <span class=\"h2\">",
"     Diabetes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The steroid effect on glucose levels begins approximately 12 hours after the first dose and may last for 5 days. Hyperglycemia related to corticosteroid administration can be severe in the diabetic gravida if not closely monitored and treated. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/62/35818?source=see_link&amp;anchor=H20#H20\">",
"     \"Obstetrical management of pregnancy complicated by pregestational diabetes mellitus\", section on 'Antenatal glucocorticoids'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     POSTNATAL SURFACTANT THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postnatal surfactant administration is not a substitute for antenatal corticosteroid therapy; in fact, antenatal corticosteroids appear to enhance the effectiveness of surfactant therapy. The benefit of sequential antenatal corticosteroid-postnatal surfactant therapy was illustrated in the Exosurf Neonatal Treatment Investigational New Drug study of 11,077 infants in whom antenatal corticosteroid treatment substantially augmented the reductions in morbidity and mortality observed with surfactant alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/55/31610/abstract/111\">",
"     111",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Antenatal corticosteroid therapy leads to improvement in neonatal lung function by enhancing maturational changes in lung architecture and by inducing lung enzymes resulting in biochemical maturation. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Mechanism of action'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Antenatal corticosteroid therapy reduces the incidence of respiratory distress syndrome, intraventricular hemorrhage, necrotizing enterocolitis, sepsis, and neonatal mortality by approximately 50 percent. These effects are not limited by gender or race; efficacy in multiple gestations is unclear, as high-quality data are sparse. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Evidence of short-term clinical efficacy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Given these benefits, we recommend administration of antenatal corticosteroids to pregnant woman who are remote from term and at increased risk of preterm delivery within the next seven days (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). In our practice, this means we restrict administration of the first course of antenatal corticosteroids to women who rupture membranes or are receiving tocolysis for active preterm labor, or in whom delivery for maternal or fetal indications is anticipated within the next seven days. This approach minimizes the need for salvage therapy while allowing the vast majority of women to receive a course of antenatal corticosteroids prior to preterm delivery. A course of antenatal corticosteroids consists of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/5/44120?source=see_link\">",
"       betamethasone",
"      </a>",
"      suspension 12 mg intramuscularly every 24 hours for two doses or four doses of 6 mg",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      intramuscularly 12 hours apart. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Drug and initial dose'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Timing before delivery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The lower limit of gestational age for administration is approximately 23 weeks since only a few primitive alveoli are present below this gestational age. Earlier administration is reasonable if aggressive neonatal intervention is planned for a delivery prior to 23 weeks of gestation. (See",
"      <a class=\"local\" href=\"#H2337777\">",
"       '23 to 34 weeks'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      After 34 weeks of gestation, we do not administer antenatal corticosteroids. If used, administration should be limited to women with documented fetal pulmonary immaturity and obstetrical issues requiring prompt delivery. (See",
"      <a class=\"local\" href=\"#H2337770\">",
"       'After 34 weeks'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The absence of consistent and long-term data precludes making an evidence-based recommendation for the number of courses that are safe for the fetus, the appropriate time interval between courses, the optimal dose for repeated courses of therapy, or the full ramifications of the single course approach to therapy. Given the potential for harm from repeated courses of antenatal corticosteroid therapy:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We suggest a single course of salvage (rescue) therapy only if the patient is clinically estimated to be at high risk of delivery within the next seven days, more than two weeks have elapsed since the initial course of antenatal corticosteroid therapy, and the gestational age at administration of the initial course was &lt;28 weeks of gestation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      We also suggest that providers who elect to give salvage (rescue) therapy use one dose of 12 mg",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/5/44120?source=see_link\">",
"       betamethasone",
"      </a>",
"      and limit treatment to this one additional dose (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). One dose appears to be effective and may minimize complications related to steroid use. Patients should be informed of potential adverse effects. (See",
"      <a class=\"local\" href=\"#H667637\">",
"       'Use of repeated courses of therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend antenatal corticosteroids for women with preterm premature rupture of membranes (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). We give steroids at 23 to 32 weeks of gestation in the absence of any clinical signs of chorioamnionitis. Some experts will administer antenatal corticosteroids at 32 to 34 weeks if pulmonary immaturity has been documented, although efficacy has not been proven. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Preterm premature rupture of membranes'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31610/abstract/1\">",
"      Liggins GC, Howie RN. A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics 1972; 50:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31610/abstract/2\">",
"      Roberts D, Dalziel S. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev 2006; :CD004454.",
"     </a>",
"    </li>",
"    <li>",
"     Report on the Consensus Development Conference on the Effect of Corticosteroids for Fetal Maturation on Perinatal Outcomes. U.S. Department of Health and Human Services, Public Health Service, NIH Pub No. 95-3784, November 1994.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31610/abstract/4\">",
"      ACOG Committee on Obstetric Practice. ACOG Committee Opinion No. 475: Antenatal corticosteroid therapy for fetal maturation. Obstet Gynecol 2011; 117:422.",
"     </a>",
"    </li>",
"    <li>",
"     RCOG Guidelines. Number 7. ACS to prevent respiratory distress syndrome. London:RCOG 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31610/abstract/6\">",
"      Smolders-de Haas H, Neuvel J, Schmand B, et al. Physical development and medical history of children who were treated antenatally with corticosteroids to prevent respiratory distress syndrome: a 10- to 12-year follow-up. Pediatrics 1990; 86:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31610/abstract/7\">",
"      Ballard PL, Ballard RA. Scientific basis and therapeutic regimens for use of antenatal glucocorticoids. Am J Obstet Gynecol 1995; 173:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31610/abstract/8\">",
"      Ballard PL. Hormonal regulation of surfactant in fetal life. Mead Johnson Symp Perinat Dev Med 1978; :25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31610/abstract/9\">",
"      Walther FJ, David-Cu R, Mehta EI, et al. Higher lung antioxidant enzyme activity persists after single dose of corticosteroids in preterm lambs. Am J Physiol 1996; 271:L187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31610/abstract/10\">",
"      Polk DH, Ikegami M, Jobe AH, et al. Preterm lung function after retreatment with antenatal betamethasone in preterm lambs. Am J Obstet Gynecol 1997; 176:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31610/abstract/11\">",
"      Vidaeff AC, Ramin SM, Gilstrap LC 3rd, Alcorn JL. In vitro quantification of dexamethasone-induced surfactant protein B expression in human lung cells. J Matern Fetal Neonatal Med 2004; 15:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31610/abstract/12\">",
"      Bunton TE, Plopper CG. Triamcinolone-induced structural alterations in the development of the lung of the fetal rhesus macaque. Am J Obstet Gynecol 1984; 148:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31610/abstract/13\">",
"      Crowley PA. Antenatal corticosteroid therapy: a meta-analysis of the randomized trials, 1972 to 1994. Am J Obstet Gynecol 1995; 173:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31610/abstract/14\">",
"      Gates S, Brocklehurst P. Decline in effectiveness of antenatal corticosteroids with time to birth: real or artefact? BMJ 2007; 335:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31610/abstract/15\">",
"      Smith LM, Altamirano AK, Ervin MG, et al. Prenatal glucocorticoid exposure and postnatal adaptation in premature newborn baboons ventilated for six days. Am J Obstet Gynecol 2004; 191:1688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31610/abstract/16\">",
"      Ballard PL, Granberg P, Ballard RA. Glucocorticoid levels in maternal and cord serum after prenatal betamethasone therapy to prevent respiratory distress syndrome. J Clin Invest 1975; 56:1548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31610/abstract/17\">",
"      Hashima JN, Lai Y, Wapner RJ, et al. The effect of maternal body mass index on neonatal outcome in women receiving a single course of antenatal corticosteroids. Am J Obstet Gynecol 2010; 202:263.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31610/abstract/18\">",
"      Gyamfi C, Mele L, Wapner RJ, et al. The effect of plurality and obesity on betamethasone concentrations in women at risk for preterm delivery. Am J Obstet Gynecol 2010; 203:219.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31610/abstract/19\">",
"      Jobe AH, Soll RF. Choice and dose of corticosteroid for antenatal treatments. Am J Obstet Gynecol 2004; 190:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31610/abstract/20\">",
"      Lee BH, Stoll BJ, McDonald SA, et al. Adverse neonatal outcomes associated with antenatal dexamethasone versus antenatal betamethasone. Pediatrics 2006; 117:1503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31610/abstract/21\">",
"      Elimian A, Garry D, Figueroa R, et al. Antenatal betamethasone compared with dexamethasone (betacode trial): a randomized controlled trial. Obstet Gynecol 2007; 110:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31610/abstract/22\">",
"      Spinillo A, Viazzo F, Colleoni R, et al. Two-year infant neurodevelopmental outcome after single or multiple antenatal courses of corticosteroids to prevent complications of prematurity. Am J Obstet Gynecol 2004; 191:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31610/abstract/23\">",
"      Baud O, Foix-L'Helias L, Kaminski M, et al. Antenatal glucocorticoid treatment and cystic periventricular leukomalacia in very premature infants. N Engl J Med 1999; 341:1190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31610/abstract/24\">",
"      O'Shea TM, Kothadia JM, Klinepeter KL, et al. Randomized placebo-controlled trial of a 42-day tapering course of dexamethasone to reduce the duration of ventilator dependency in very low birth weight infants: outcome of study participants at 1-year adjusted age. Pediatrics 1999; 104:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31610/abstract/25\">",
"      Reist M, Marshall KA, Jenner P, Halliwell B. Toxic effects of sulphite in combination with peroxynitrite on neuronal cells. J Neurochem 1998; 71:2431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31610/abstract/26\">",
"      Haynes LE, Griffiths MR, Hyde RE, et al. Dexamethasone induces limited apoptosis and extensive sublethal damage to specific subregions of the striatum and hippocampus: implications for mood disorders. Neuroscience 2001; 104:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31610/abstract/27\">",
"      Murphy BP, Inder TE, Huppi PS, et al. Impaired cerebral cortical gray matter growth after treatment with dexamethasone for neonatal chronic lung disease. Pediatrics 2001; 107:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31610/abstract/28\">",
"      Lee BH, Stoll BJ, McDonald SA, et al. Neurodevelopmental outcomes of extremely low birth weight infants exposed prenatally to dexamethasone versus betamethasone. Pediatrics 2008; 121:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31610/abstract/29\">",
"      Yeh TF, Lin YJ, Lin HC, et al. Outcomes at school age after postnatal dexamethasone therapy for lung disease of prematurity. N Engl J Med 2004; 350:1304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31610/abstract/30\">",
"      Liu J, Feng ZC, Li J, Wang Q. Antenatal dexamethasone has no adverse effects on child physical and cognitive development: a long-term cohort follow-up investigation. J Matern Fetal Neonatal Med 2012; 25:2369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31610/abstract/31\">",
"      Baud O, Laudenbach V, Evrard P, Gressens P. Neurotoxic effects of fluorinated glucocorticoid preparations on the developing mouse brain: role of preservatives. Pediatr Res 2001; 50:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31610/abstract/32\">",
"      Dani C, Vestri V, Bertini G, et al. Toxicity of corticosteroids and catecholamines for mice neuronal cell cultures: Role of preservatives. J Matern Fetal Neonatal Med 2007; 20:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31610/abstract/33\">",
"      Brownfoot FC, Crowther CA, Middleton P. Different corticosteroids and regimens for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev 2008; :CD006764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31610/abstract/34\">",
"      Moore LE, Martin JN Jr. When betamethasone and dexamethasone are unavailable: hydrocortisone. J Perinatol 2001; 21:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31610/abstract/35\">",
"      Morrison JC, Whybrew WD, Bucovaz ET, Schneider JM. Injection of corticosteroids into mother to prevent neonatal respiratory distress syndrome. Am J Obstet Gynecol 1978; 131:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31610/abstract/36\">",
"      Carlo WA, McDonald SA, Fanaroff AA, et al. Association of antenatal corticosteroids with mortality and neurodevelopmental outcomes among infants born at 22 to 25 weeks' gestation. JAMA 2011; 306:2348.",
"     </a>",
"    </li>",
"    <li>",
"     Moore KL, Persaud TVN. The respiratory system. In: The Developing Human, 5th ed, WB Saunders, Philadelphia 1993. p.226.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31610/abstract/38\">",
"      Stutchfield P, Whitaker R, Russell I, Antenatal Steroids for Term Elective Caesarean Section (ASTECS) Research Team. Antenatal betamethasone and incidence of neonatal respiratory distress after elective caesarean section: pragmatic randomised trial. BMJ 2005; 331:662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31610/abstract/39\">",
"      Shanks A, Gross G, Shim T, et al. Administration of steroids after 34 weeks of gestation enhances fetal lung maturity profiles. Am J Obstet Gynecol 2010; 203:47.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31610/abstract/40\">",
"      Porto AM, Coutinho IC, Correia JB, Amorim MM. Effectiveness of antenatal corticosteroids in reducing respiratory disorders in late preterm infants: randomised clinical trial. BMJ 2011; 342:d1696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31610/abstract/41\">",
"      Stutchfield PR, Whitaker R, Gliddon AE, et al. Behavioural, educational and respiratory outcomes of antenatal betamethasone for term caesarean section (ASTECS trial). Arch Dis Child Fetal Neonatal Ed 2013; 98:F195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31610/abstract/42\">",
"      American College of Obstetricians and Gynecologists, Committee on Practice Bulletins&mdash;Obstetrics. ACOG practice bulletin no. 127: Management of preterm labor. Obstet Gynecol 2012; 119:1308.",
"     </a>",
"    </li>",
"    <li>",
"     2010 Antenatal corticosteroids to reduce neonatal morbidity and mortality. Greentop Guideline no 7. London: Royal College of Obstetricians and Gynaecologists. Available at www.rcog.org.uk (Accessed on October 18, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31610/abstract/44\">",
"      Gross I, Ballard PL, Ballard RA, et al. Corticosteroid stimulation of phosphatidylcholine synthesis in cultured fetal rabbit lung: evidence for de novo protein synthesis mediated by glucocorticoid receptors. Endocrinology 1983; 112:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31610/abstract/45\">",
"      Ikegami M, Polk D, Jobe A. Minimum interval from fetal betamethasone treatment to postnatal lung responses in preterm lambs. Am J Obstet Gynecol 1996; 174:1408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31610/abstract/46\">",
"      Elimian A, Figueroa R, Spitzer AR, et al. Antenatal corticosteroids: are incomplete courses beneficial? Obstet Gynecol 2003; 102:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31610/abstract/47\">",
"      Subtil D, Tiberghien P, Devos P, et al. Immediate and delayed effects of antenatal corticosteroids on fetal heart rate: a randomized trial that compares betamethasone acetate and phosphate, betamethasone phosphate, and dexamethasone. Am J Obstet Gynecol 2003; 188:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31610/abstract/48\">",
"      Mulder EJ, Derks JB, Visser GH. Antenatal corticosteroid therapy and fetal behaviour: a randomised study of the effects of betamethasone and dexamethasone. Br J Obstet Gynaecol 1997; 104:1239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31610/abstract/49\">",
"      Senat MV, Minoui S, Multon O, et al. Effect of dexamethasone and betamethasone on fetal heart rate variability in preterm labour: a randomised study. Br J Obstet Gynaecol 1998; 105:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31610/abstract/50\">",
"      Rotmensch S, Liberati M, Vishne TH, et al. The effect of betamethasone and dexamethasone on fetal heart rate patterns and biophysical activities. A prospective randomized trial. Acta Obstet Gynecol Scand 1999; 78:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31610/abstract/51\">",
"      Rotmensch S, Lev S, Kovo M, et al. Effect of betamethasone administration on fetal heart rate tracing: a blinded longitudinal study. Fetal Diagn Ther 2005; 20:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31610/abstract/52\">",
"      Kelly MK, Schneider EP, Petrikovsky BM, Lesser ML. Effect of antenatal steroid administration on the fetal biophysical profile. J Clin Ultrasound 2000; 28:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31610/abstract/53\">",
"      Rotmensch S, Liberati M, Celentano C, et al. The effect of betamethasone on fetal biophysical activities and Doppler velocimetry of umbilical and middle cerebral arteries. Acta Obstet Gynecol Scand 1999; 78:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31610/abstract/54\">",
"      Katz M, Meizner I, Holcberg G, et al. Reduction or cessation of fetal movements after administration of steroids for enhancement of lung maturation. I. Clinical evaluation. Isr J Med Sci 1988; 24:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31610/abstract/55\">",
"      Schwab M, Coksaygan T, Nathanielsz PW. Betamethasone effects on ovine uterine and umbilical placental perfusion at the dose used to enhance fetal lung maturation. Am J Obstet Gynecol 2006; 194:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31610/abstract/56\">",
"      Derks JB, Giussani DA, Jenkins SL, et al. A comparative study of cardiovascular, endocrine and behavioural effects of betamethasone and dexamethasone administration to fetal sheep. J Physiol 1997; 499 ( Pt 1):217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31610/abstract/57\">",
"      Koenen SV, Mecenas CA, Smith GS, et al. Effects of maternal betamethasone administration on fetal and maternal blood pressure and heart rate in the baboon at 0.7 of gestation. Am J Obstet Gynecol 2002; 186:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31610/abstract/58\">",
"      Smith RP, Miller SL, Igosheva N, et al. Cardiovascular and endocrine responses to cutaneous electrical stimulation after fentanyl in the ovine fetus. Am J Obstet Gynecol 2004; 190:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31610/abstract/59\">",
"      Miller SL, Supramaniam VG, Jenkin G, et al. Cardiovascular responses to maternal betamethasone administration in the intrauterine growth-restricted ovine fetus. Am J Obstet Gynecol 2009; 201:613.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31610/abstract/60\">",
"      Edwards A, Baker LS, Wallace EM. Changes in umbilical artery flow velocity waveforms following maternal administration of betamethasone. Placenta 2003; 24:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31610/abstract/61\">",
"      Robertson MC, Murila F, Tong S, et al. Predicting perinatal outcome through changes in umbilical artery Doppler studies after antenatal corticosteroids in the growth-restricted fetus. Obstet Gynecol 2009; 113:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31610/abstract/62\">",
"      Wallace EM, Baker LS. Effect of antenatal betamethasone administration on placental vascular resistance. Lancet 1999; 353:1404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31610/abstract/63\">",
"      Wijnberger LD, Bilardo CM, Hecher K, et al. Effect of antenatal glucocorticoid therapy on arterial and venous blood flow velocity waveforms in severely growth-restricted fetuses. Ultrasound Obstet Gynecol 2004; 23:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31610/abstract/64\">",
"      Simchen MJ, Alkazaleh F, Adamson SL, et al. The fetal cardiovascular response to antenatal steroids in severe early-onset intrauterine growth restriction. Am J Obstet Gynecol 2004; 190:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31610/abstract/65\">",
"      Banks BA, Cnaan A, Morgan MA, et al. Multiple courses of antenatal corticosteroids and outcome of premature neonates. North American Thyrotropin-Releasing Hormone Study Group. Am J Obstet Gynecol 1999; 181:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31610/abstract/66\">",
"      Ashwood PJ, Crowther CA, Willson KJ, et al. Neonatal adrenal function after repeat dose prenatal corticosteroids: a randomized controlled trial. Am J Obstet Gynecol 2006; 194:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31610/abstract/67\">",
"      Davis EP, Townsend EL, Gunnar MR, et al. Effects of prenatal betamethasone exposure on regulation of stress physiology in healthy premature infants. Psychoneuroendocrinology 2004; 29:1028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31610/abstract/68\">",
"      Sch&auml;ffer L, Luzi F, Burkhardt T, et al. Antenatal betamethasone administration alters stress physiology in healthy neonates. Obstet Gynecol 2009; 113:1082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31610/abstract/69\">",
"      Waffarn F, Davis EP. Effects of antenatal corticosteroids on the hypothalamic-pituitary-adrenocortical axis of the fetus and newborn: experimental findings and clinical considerations. Am J Obstet Gynecol 2012; 207:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31610/abstract/70\">",
"      Effects of antenatal dexamethasone administration in the infant: long-term follow-up. J Pediatr 1984; 104:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31610/abstract/71\">",
"      Doyle LW, Kitchen WH, Ford GW, et al. Antenatal steroid therapy and 5-year outcome of extremely low birth weight infants. Obstet Gynecol 1989; 73:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31610/abstract/72\">",
"      MacArthur BA, Howie RN, Dezoete JA, Elkins J. School progress and cognitive development of 6-year-old children whose mothers were treated antenatally with betamethasone. Pediatrics 1982; 70:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31610/abstract/73\">",
"      Dessens AB, Haas HS, Koppe JG. Twenty-year follow-up of antenatal corticosteroid treatment. Pediatrics 2000; 105:E77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31610/abstract/74\">",
"      Dalziel SR, Walker NK, Parag V, et al. Cardiovascular risk factors after antenatal exposure to betamethasone: 30-year follow-up of a randomised controlled trial. Lancet 2005; 365:1856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31610/abstract/75\">",
"      Dalziel SR, Lim VK, Lambert A, et al. Antenatal exposure to betamethasone: psychological functioning and health related quality of life 31 years after inclusion in randomised controlled trial. BMJ 2005; 331:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31610/abstract/76\">",
"      Alexander N, Rosenl&ouml;cher F, Stalder T, et al. Impact of antenatal synthetic glucocorticoid exposure on endocrine stress reactivity in term-born children. J Clin Endocrinol Metab 2012; 97:3538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31610/abstract/77\">",
"      Kelly BA, Lewandowski AJ, Worton SA, et al. Antenatal glucocorticoid exposure and long-term alterations in aortic function and glucose metabolism. Pediatrics 2012; 129:e1282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31610/abstract/78\">",
"      Stubblefield PG. Pulmonary edema occurring after therapy with dexamethasone and terbutaline for premature labor: a case report. Am J Obstet Gynecol 1978; 132:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31610/abstract/79\">",
"      Ogburn PL Jr, Julian TM, Williams PP, Thompson TR. The use of magnesium sulfate for tocolysis in preterm labor complicated by twin gestation and betamimetic-induced pulmonary edema. Acta Obstet Gynecol Scand 1986; 65:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31610/abstract/80\">",
"      Ogunyemi D. Risk factors for acute pulmonary edema in preterm delivery. Eur J Obstet Gynecol Reprod Biol 2007; 133:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31610/abstract/81\">",
"      Amorim MM, Santos LC, Fa&uacute;ndes A. Corticosteroid therapy for prevention of respiratory distress syndrome in severe preeclampsia. Am J Obstet Gynecol 1999; 180:1283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31610/abstract/82\">",
"      Mastrobattista JM, Patel N, Monga M. Betamethasone alteration of the one-hour glucose challenge test in pregnancy. J Reprod Med 2001; 46:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31610/abstract/83\">",
"      Gurbuz A, Karateke A, Ozturk G, Kabaca C. Is 1-hour glucose screening test reliable after a short-term administration of antenatal betamethasone? Am J Perinatol 2004; 21:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31610/abstract/84\">",
"      Vaisbuch E, Levy R, Hagay Z. The effect of betamethasone administration to pregnant women on maternal serum indicators of infection. J Perinat Med 2002; 30:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31610/abstract/85\">",
"      Kadanali S, Inge&ccedil; M, K&uuml;&ccedil;&uuml;k&ouml;zkan T, et al. Changes in leukocyte, granulocyte and lymphocyte counts following antenatal betamethasone administration to pregnant women. Int J Gynaecol Obstet 1997; 58:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31610/abstract/86\">",
"      Crowther CA, McKinlay CJ, Middleton P, Harding JE. Repeat doses of prenatal corticosteroids for women at risk of preterm birth for improving neonatal health outcomes. Cochrane Database Syst Rev 2011; :CD003935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31610/abstract/87\">",
"      Wapner RJ, Sorokin Y, Thom EA, et al. Single versus weekly courses of antenatal corticosteroids: evaluation of safety and efficacy. Am J Obstet Gynecol 2006; 195:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31610/abstract/88\">",
"      Sawady J, Mercer BM, Wapner RJ, et al. The National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network Beneficial Effects of Antenatal Repeated Steroids study: impact of repeated doses of antenatal corticosteroids on placental growth and histologic findings. Am J Obstet Gynecol 2007; 197:281.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31610/abstract/89\">",
"      Murphy KE, Willan AR, Hannah ME, et al. Effect of antenatal corticosteroids on fetal growth and gestational age at birth. Obstet Gynecol 2012; 119:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31610/abstract/90\">",
"      Murphy KE, Hannah ME, Willan AR, et al. Maternal side-effects after multiple courses of antenatal corticosteroids (MACS): the three-month follow-up of women in the randomized controlled trial of MACS for preterm birth study. J Obstet Gynaecol Can 2011; 33:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31610/abstract/91\">",
"      Battin M, Bevan C, Harding J. Growth in the neonatal period after repeat courses of antenatal corticosteroids: data from the ACTORDS randomised trial. Arch Dis Child Fetal Neonatal Ed 2012; 97:F99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31610/abstract/92\">",
"      Peltoniemi OM, Kari MA, Tammela O, et al. Randomized trial of a single repeat dose of prenatal betamethasone treatment in imminent preterm birth. Pediatrics 2007; 119:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31610/abstract/93\">",
"      Garite TJ, Kurtzman J, Maurel K, et al. Impact of a 'rescue course' of antenatal corticosteroids: a multicenter randomized placebo-controlled trial. Am J Obstet Gynecol 2009; 200:248.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31610/abstract/94\">",
"      McEvoy C, Schilling D, Peters D, et al. Respiratory compliance in preterm infants after a single rescue course of antenatal steroids: a randomized controlled trial. Am J Obstet Gynecol 2010; 202:544.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31610/abstract/95\">",
"      Crowther CA, Haslam RR, Hiller JE, et al. Neonatal respiratory distress syndrome after repeat exposure to antenatal corticosteroids: a randomised controlled trial. Lancet 2006; 367:1913.",
"     </a>",
"    </li>",
"    <li>",
"     Ballard PL. Hormones and lung maturation. In: Monographs on Endocrinology, Springer-Verlag, Berlin 1986. Vol 28, p.1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31610/abstract/97\">",
"      Ballard PL, Ballard RA. Glucocorticoid receptors and the role of glucocorticoids in fetal lung development. Proc Natl Acad Sci U S A 1972; 69:2668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31610/abstract/98\">",
"      Oakley RH, Cidlowski JA. Homologous down regulation of the glucocorticoid receptor: the molecular machinery. Crit Rev Eukaryot Gene Expr 1993; 3:63.",
"     </a>",
"    </li>",
"    <li>",
"     Howie RN, Liggins GC. The New Zealand study of antepartum glucocorticoid treatment. In: Lung development: biological and clinical perspectives, Farrell PM (Ed), Academic Press, New York 1983. Vol 2, p.255.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31610/abstract/100\">",
"      Khandelwal M, Chang E, Hansen C, et al. Betamethasone dosing interval: 12 or 24 hours apart? A randomized, noninferiority open trial. Am J Obstet Gynecol 2012; 206:201.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31610/abstract/101\">",
"      Haas DM, McCullough W, McNamara MF, Olsen C. The first 48 hours: Comparing 12-hour and 24-hour betamethasone dosing when preterm deliveries occur rapidly. J Matern Fetal Neonatal Med 2006; 19:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31610/abstract/102\">",
"      Egerman RS, Mercer BM, Doss JL, Sibai BM. A randomized, controlled trial of oral and intramuscular dexamethasone in the prevention of neonatal respiratory distress syndrome. Am J Obstet Gynecol 1998; 179:1120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31610/abstract/103\">",
"      Spellacy WN, Buhi WC, Riggall FC, Holsinger KL. Human amniotic fluid lecithin-sphingomyelin ratio changes with estrogen or glucocorticoid treatment. Am J Obstet Gynecol 1973; 115:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31610/abstract/104\">",
"      Piazze JJ, Maranghi L, Nigro G, et al. The effect of glucocorticoid therapy on fetal lung maturity indices in hypertensive pregnancies. Obstet Gynecol 1998; 92:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31610/abstract/105\">",
"      Effect of antenatal dexamethasone administration on the prevention of respiratory distress syndrome. Am J Obstet Gynecol 1981; 141:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31610/abstract/106\">",
"      Farrell PM, Engle MJ, Zachman RD, et al. Amniotic fluid phospholipids after maternal administration of dexamethasone. Am J Obstet Gynecol 1983; 145:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31610/abstract/107\">",
"      Harding JE, Pang J, Knight DB, Liggins GC. Do antenatal corticosteroids help in the setting of preterm rupture of membranes? Am J Obstet Gynecol 2001; 184:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31610/abstract/108\">",
"      Guinn DA, Atkinson MW, Sullivan L, et al. Single vs weekly courses of antenatal corticosteroids for women at risk of preterm delivery: A randomized controlled trial. JAMA 2001; 286:1581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31610/abstract/109\">",
"      Lee MJ, Davies J, Guinn D, et al. Single versus weekly courses of antenatal corticosteroids in preterm premature rupture of membranes. Obstet Gynecol 2004; 103:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31610/abstract/110\">",
"      Della Torre M, Hibbard JU, Jeong H, Fischer JH. Betamethasone in pregnancy: influence of maternal body weight and multiple gestation on pharmacokinetics. Am J Obstet Gynecol 2010; 203:254.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/55/31610/abstract/111\">",
"      Andrews EB, Marcucci G, White A, Long W. Associations between use of antenatal corticosteroids and neonatal outcomes within the Exosurf Neonatal Treatment Investigational New Drug Program. Am J Obstet Gynecol 1995; 173:290.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6796 Version 24.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-190.111.122.2-14B9D587E9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_55_31610=[""].join("\n");
var outline_f30_55_31610=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MECHANISM OF ACTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EVIDENCE OF SHORT-TERM CLINICAL EFFICACY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Reduction of RDS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Reduction of IVH, NEC, NNM, infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DRUG AND INITIAL DOSE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Betamethasone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Dexamethasone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Comparative studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22617742\">",
"      Hydrocortisone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      GESTATIONAL AGE AT ADMINISTRATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2337777\">",
"      23 to 34 weeks",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2337770\">",
"      After 34 weeks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      TIMING BEFORE DELIVERY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SAFETY AND SIDE EFFECTS OF A SINGLE COURSE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Potential fetal side effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1498435\">",
"      Potential long-term side effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22617614\">",
"      - Infants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Children and adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Maternal side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H667637\">",
"      USE OF REPEATED COURSES OF THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6150007\">",
"      Salvage (rescue) therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      ALTERNATIVE DOSING REGIMENS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Higher dose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21501907\">",
"      Shorter dosing interval",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Intravenous administration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Oral administration of dexamethasone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      AMNIOCENTESIS AFTER ANTENATAL CORTICOSTEROID THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10508471\">",
"      SPECIAL POPULATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Preterm premature rupture of membranes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10508416\">",
"      Multiple gestation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18289464\">",
"      Hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18289519\">",
"      Diabetes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      POSTNATAL SURFACTANT THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/6796\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/6796|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?39/31/40446\" title=\"figure 1\">",
"      Glucocorticoid action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/6796|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?5/62/6124\" title=\"table 1\">",
"      NIH recommendationsfor antenatal steroids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?20/4/20555\" title=\"table 2A\">",
"      Betamethasone vs dexamethasone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?10/39/10875\" title=\"table 2B\">",
"      Betamethasone vs dexamethasone2",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/58/42919?source=related_link\">",
"      Assessment of fetal lung maturity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/62/35818?source=related_link\">",
"      Obstetrical management of pregnancy complicated by pregestational diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/31/15866?source=related_link\">",
"      Preterm premature rupture of membranes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/46/40682?source=related_link\">",
"      Twin pregnancy: Prenatal issues",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_55_31611="Hidradenitis suppurativa - associated disorders";
var content_f30_55_31611=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F75490&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F75490&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Disorders associated with hidradenitis suppurativa",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Autoimmune/inflammatory disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Crohn disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ulcerative colitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SAPHO syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pyoderma gangrenosum",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Beh&ccedil;et's disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Spondylarthropathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acne conglobata alone or in the setting of the follicular occlusion triad*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Malignancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Squamous cell carcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Adenocarcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Genetic disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pachyonychia congenita",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dowling-Degos disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Keratitis-ichthyosis-deafness (KID) syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Down syndrome",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * The follicular occlusion triad consists of hidradenitis suppurativa, acne conglobata, and dissecting cellulitis of the scalp.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Fimmel S, Zouboulis CC. Comorbidities of hidradenitis suppurativa (acne inversa). Dermatoendocrinol 2010; 2:9.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_55_31611=[""].join("\n");
var outline_f30_55_31611=null;
var title_f30_55_31612="DDx BPLL path";
var content_f30_55_31612=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F54944&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F54944&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of B cell prolymphocytic leukemia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Entity",
"      </td>",
"      <td class=\"subtitle1\">",
"       Histology",
"      </td>",
"      <td class=\"subtitle1\">",
"       Immunophenotype",
"      </td>",
"      <td class=\"subtitle1\">",
"       Genetic features/Other",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       B cell prolymphocytic leukemia",
"      </td>",
"      <td>",
"       <p>",
"        &gt;55 percent (and usually &gt;90 percent) of circulating white cells are \"prolymphocytes\": medium-sized cells with moderately abundant, slightly basophilic cytoplasm; a round or oval nucleus with moderately condensed chromatin; and a single, prominent nucleolus.",
"       </p>",
"       <p>",
"        The bone marrow is infiltrated in an interstitial or nodular pattern by similar cells.",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        Express bright surface IgM +/- IgD and bright CD20 as well as other B-cell antigens (CD19, CD22, CD79a, FMC7).",
"       </p>",
"       <p>",
"        CD5 and CD23 expression is usually weak or absent. CD11c, CD103, CD10, CD25, and cyclin D1 are not expressed.",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        t(11;14) must be excluded.",
"       </p>",
"       <p>",
"        No associated paraproteinemia.",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Chronic lymphocytic leukemia/Small lymphocytic lymphoma",
"      </td>",
"      <td>",
"       <p>",
"        \"Typical\" CLL cells are small mature appearing lymphocytes with a dense nucleus, partially aggregated chromatin, no discernible nucleoli, and a narrow border of clear to slightly basophilic cytoplasm.",
"       </p>",
"       <p>",
"        \"Prolymphocytes\" may be present, but are &lt;55 percent of circulating cells.",
"       </p>",
"      </td>",
"      <td>",
"       Typically express CD5 and CD23. Expression of CD20 and surface immunoglobulin is dim.",
"      </td>",
"      <td>",
"       Trisomy 12, deletions of 6q, 11q, 13q, and 17p",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T cell prolymphocytic leukemia",
"      </td>",
"      <td>",
"       Similar morphologic appearance to B-PLL.",
"      </td>",
"      <td>",
"       Expresses pan-T cell antigens (CD2, CD3, CD5, CD7).",
"      </td>",
"      <td>",
"       inv(14q)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Mantle cell lymphoma",
"      </td>",
"      <td>",
"       Can have a leukemic phase that mimics B-PLL morphologically.",
"      </td>",
"      <td>",
"       <p>",
"        Typically CD20 and CD5 positive and CD23 negative.",
"       </p>",
"       <p>",
"        Express cyclin D1.",
"       </p>",
"      </td>",
"      <td>",
"       t(11;14)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Follicular lymphoma",
"      </td>",
"      <td>",
"       Circulating centrocytes have highly irregular or cleaved nuclear contours.",
"      </td>",
"      <td>",
"       Typically expresses CD10.",
"      </td>",
"      <td>",
"       t(14;18)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Lymphoplasmacytic lymphoma",
"      </td>",
"      <td>",
"       Occasionally associated with circulating malignant cells with a plasmacytoid appearance.",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       Often associated with a paraproteinemia.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hairy cell leukemia",
"      </td>",
"      <td>",
"       Variant has circulating tumor cells with morphology intermediate between hairy cells and prolymphocytes.",
"      </td>",
"      <td>",
"       Unlike B-PLL, most cases of HCL express CD11c, CD103, CD123, cyclin D1, and/or annexin A1. Express the interleukin-2 receptor beta chain, but not the alpha chain (CD25).",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_55_31612=[""].join("\n");
var outline_f30_55_31612=null;
var title_f30_55_31613="B cell surface markers I";
var content_f30_55_31613=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F78500&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F78500&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Surface markers during B cell development-I",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        &nbsp;&nbsp;",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"5\">",
"        Antigen-independent phase",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"4\">",
"        Antigen-dependent phase",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Pre-pro B cell",
"       </td>",
"       <td class=\"subtitle2\">",
"        Pro-B cell",
"       </td>",
"       <td class=\"subtitle2\">",
"        Pre B cell",
"       </td>",
"       <td class=\"subtitle2\">",
"        Immature B cell",
"       </td>",
"       <td class=\"subtitle2\">",
"        Mature B cell",
"       </td>",
"       <td class=\"subtitle2\">",
"        Activated B cell",
"       </td>",
"       <td class=\"subtitle2\">",
"        Blast B cell",
"       </td>",
"       <td class=\"subtitle2\">",
"        Memory B cell",
"       </td>",
"       <td class=\"subtitle2\">",
"        Plasma B cell",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        MHC Class II",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CD10",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CD19",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CD20",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CD21",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CD23",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CD25, IL-2R alpha",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CD32, Fc gamma RII",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CD34",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CD35, CR1",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CD40",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CD80/86, B7-1/2",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     IL: interleukin; R: receptor; alpha: alpha chain.",
"    </div>",
"    <div class=\"reference\">",
"     Data from Bona, CA, Bonilla, FA, Textbook of Immunology, 2nd edition, Harwood Academic Publishers, Amsterdam, 1996. page 102 (no table number).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_55_31613=[""].join("\n");
var outline_f30_55_31613=null;
var title_f30_55_31614="TIMI risk score for non-ST elevation ACS";
var content_f30_55_31614=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F67473&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F67473&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 498px\">",
"   <div class=\"ttl\">",
"    TIMI risk score for non-ST elevation ACS",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 478px; height: 498px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Rates of all-cause mortality, myocardial infarction, and severe recurrent ischemia prompting urgent revascularization at 14 days after randomization according to the number of risk factors among patients with a non-ST elevation acute coronary syndrome (ACS) in TIMI 11B and ESSENCE. The risk factors were age &ge;65 years; presence of at least three risk factors for coronary disease; prior coronary stenosis of &ge;50 percent; presence of ST segment deviation on admission ECG; at least two anginal episodes in prior 24 hours; use of aspirin in prior seven days; and elevated serum cardiac biomarkers. Event rates increased significantly as the TIMI risk score rose. Patients are considered to be at low risk with a score of 0 to 2; intermediate risk with a score of 3 to 4; and high risk with a score of 5 to 7.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Antman EM, Cohen M, Bernink PJ, et al. JAMA 2000; 284:835.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_55_31614=[""].join("\n");
var outline_f30_55_31614=null;
var title_f30_55_31615="Thumb spica splint";
var content_f30_55_31615=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F81987&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F81987&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Thumb spica splint",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 383px; height: 322px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The thumb spica splint provides&nbsp;excellent immobilization for the thumb. It is often used for carpometacarpal osteoarthritis, de Quervain's tenosynovitis, ulnar collateral ligament injury (gamekeeper's or skier's&nbsp;thumb), and fractures of the scaphoid, trapezium, and first metacarpal.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Bruce C Anderson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_55_31615=[""].join("\n");
var outline_f30_55_31615=null;
